

# CITATION REPORT

List of articles citing

## Chronic Parkinsonism secondary to intravenous injection of meperidine analogues

DOI: 10.1016/0165-1781(79)90006-4  
Psychiatry Research, 1979, 1, 249-54.

**Source:** <https://exaly.com/paper-pdf/14233202/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1226	Juvenile Parkinsonism and Other Dopa-Responsive Syndromes. <b>1995</b> , 14, 25-35		1
1225	Opioid analgesics and narcotic antagonists. <b>1981</b> , 5, 63-75		
1224	Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. <b>1983</b> , 219, 979-80		3972
1223	Management of extrapyramidal disease in the family medicine clinic. <b>1983</b> , 11, 163-6		1
1222	Aetiology of Parkinson's disease. <b>1983</b> , 2, 1457-9		361
1221	Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. <b>1983</b> , 309, 310		240
1220	A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1983</b> , 80, 4546-50		1647
1219	Current views on Parkinson's disease. <b>1983</b> , 10, 11-5		9
1218	Etiology of Parkinson's disease: A research strategy. <b>1984</b> , 11, 24-8		96
1217	Defective utilization of sensory input as the basis for bradykinesia, rigidity and decreased movement repertoire in Parkinson's disease: a hypothesis. <b>1984</b> , 11, 136-43		61
1216	Chronic Parkinsonism Secondary to Intranasal Administration of a Product of Meperidine-Analogue Synthesis. <b>1984</b> , 310, 325-325		16
1215	Inhibition of dihydropteridine reductase by novel 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs. <b>1984</b> , 224, 405-7		30
1214	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine destroys dopamine neurons in explants of rat embryo mesencephalon. <b>1984</b> , 225, 529-31		107
1213	Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. <b>1984</b> , 311, 464-7		709
1212	Parkinson's disease. Clues to aetiology from a toxin. <b>1984</b> , 311, 514		12
1211	Melanin affinity of manganese. <b>1984</b> , 55, 133-8		54
1210	Conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) and its 5-methyl analog into pyridinium salts. <b>1984</b> , 67, 2037-2042		31

1209	Biochemical and functional evidence for a marked dopamine releasing action of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) in mouse brain. <b>1984</b> , 60, 199-203	40
1208	Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. <b>1984</b> , 35, 285-91	67
1207	Assessment of the opiate properties of two constituents of a toxic illicit drug mixture. <b>1984</b> , 13, 367-74	13
1206	Parkinson's Disease, 1984. <b>1984</b> , 323, 829-830	2
1205	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. <b>1984</b> , 50, 85-90	304
1204	N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) affects locomotor activity without producing a nigrostriatal lesion in the rat. <b>1984</b> , 48, 179-84	49
1203	MPTP alters central catecholamine neurons in addition to the nigrostriatal system. <b>1984</b> , 13, 737-42	49
1202	Anti-parkinsonian drugs today. <b>1984</b> , 28, 236-62	40
1201	Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. <b>1984</b> , 224, 1451-3	963
1200	Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP. <b>1984</b> , 101, 37-44	47
1199	Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. <b>1984</b> , 100, 189-94	186
1198	In vitro release of tritiated monoamines from rat CNS tissue by the neurotoxic compound 1-methyl-phenyl-tetrahydropyridine. <b>1984</b> , 103, 255-60	43
1197	Neurotoxicity of the meperidine analogue N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. <b>1984</b> , 97, 133-6	175
1196	Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in preparations of rat brain. <b>1984</b> , 106, 301-11	21
1195	Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1984</b> , 33, 2957-60	36
1194	The possible relation of glutathione, melanin and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) to Parkinson's disease. <b>1984</b> , 33, 2697-8	45
1193	Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse liver preparations. <b>1984</b> , 125, 484-90	31
1192	Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. <b>1984</b> , 33, 1747-52	99

1191	Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. <b>1984</b> , 34, 2567-75	18
1190	Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey. <b>1984</b> , 292, 390-4	860
1189	The importance of the '4-5' double bond for neurotoxicity in primates of the pyridine derivative MPTP. <b>1984</b> , 50, 289-94	46
1188	The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the monkey and man. <b>1984</b> , 11, 166-8	125
1187	Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. <b>1984</b> , 11, 160-5	242
1186	MPTP parkinsonism. <b>1984</b> , 289, 1401-2	21
1185	Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. <b>1984</b> , 81, 4591-5	91
1184	Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. <b>1985</b> , 82, 2173-7	1024
1183	Predicting Parkinson's disease. <b>1985</b> , 317, 198-9	81
1182	Neurochemical and histochemical characterization of neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurones in the mouse. <b>1985</b> , 44, 117-27	269
1181	Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and related compounds on the uptake of [3H]3,4-dihydroxyphenylethylamine and [3H]5-hydroxytryptamine in neostriatal synaptosomal preparations. <b>1985</b> , 44, 310-3	45
1180	Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. <b>1985</b> , 45, 1951-3	107
1179	Electrophysiological and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. <b>1985</b> , 331, 1-6	15
1178	Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. <b>1985</b> , 64, 113-27	423
1177	Structure of a Neurotoxin that Induces Parkinsonism Symptoms; l-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine Hydrochloride. <b>1985</b> , 2, 192-4	3
1176	Autoradiography of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): uptake in the monoaminergic pathways and in melanin containing tissues. <b>1985</b> , 57, 130-5	28
1175	The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1985</b> , 312, 1418-21	179
1174	Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. <b>1985</b> , 60, 109-14	169

1173	Normal MPTP binding in parkinsonian substantia nigra: evidence for extraneuronal toxin conversion in human brain. <b>1985</b> , 1, 956-7	37
1172	POSTER COMMUNICATIONS. <b>1985</b> , 86, 444P-524P	
1171	Communications. <b>1985</b> , 84, 1P-77P	1
1170	COMMUNICATIONS. <b>1985</b> , 84, 1P-77P	1
1169	In vitro oxidation of MPTP by primate neural tissue: A potential model of MPTP neurotoxicity. <b>1985</b> , 7, 169-76	12
1168	MPTP neurotoxicity: an overview and characterization of phases of toxicity. <b>1985</b> , 36, 201-6	105
1167	Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?. <b>1985</b> , 36, 207-12	147
1166	Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. <b>1985</b> , 36, 213-8	117
1165	Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. <b>1985</b> , 36, 219-24	189
1164	Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1985</b> , 36, 225-30	132
1163	Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity. <b>1985</b> , 36, 231-6	82
1162	Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1985</b> , 36, 237-42	33
1161	Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine. <b>1985</b> , 36, 249-54	48
1160	The protective effect of 1-tert.butyl-4,4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1985</b> , 37, 1195-200	21
1159	Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. <b>1985</b> , 36, 2503-8	1007
1158	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) does not destroy nigrostriatal neurons in the scorbutic guinea pig. <b>1985</b> , 36, 1233-8	35
1157	HPLC-assay with electrochemical detection for the neurotoxin MPTP, its metabolite MPP+ and MPTP-analogues in biological samples after purification over Sephadex G10. <b>1985</b> , 37, 1633-40	15
1156	New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1985</b> , 36, 1125-34	55

1155	MPTP and parkinson's disease. <b>1985</b> , 8, 79-83	122
1154	Neurological consequence of industrial exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1985</b> , 1, 747	20
1153	Participation of brain monoamine oxidase B form in the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity. <b>1985</b> , 58, 195-200	54
1152	Red cells under zero gravity. <b>1985</b> , 1, 747-8	7
1151	Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. <b>1985</b> , 61, 195-200	151
1150	Effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its metabolite, N-methyl-4-phenylpyridinium ion, on dopaminergic nigrostriatal neurons in the mouse. <b>1985</b> , 58, 321-6	47
1149	Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?. <b>1985</b> , 55, 179-84	110
1148	1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture. <b>1985</b> , 57, 19-24	79
1147	Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset. <b>1985</b> , 58, 123-6	19
1146	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. <b>1985</b> , 58, 133-7	33
1145	Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. <b>1985</b> , 62, 389-94	242
1144	Production in nature of compound resembling methylphenyltetrahydropyridine, a possible cause of Parkinson's disease. <b>1985</b> , 1, 215-6	18
1143	Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. <b>1985</b> , 2, 1213-6	182
1142	Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. <b>1985</b> , 59, 259-64	105
1141	Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. <b>1985</b> , 24, 587-91	114
1140	Catecholamine-uptake inhibitors prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain. <b>1985</b> , 24, 689-92	82
1139	Spinal cord metabolism of the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkey. <b>1985</b> , 337, 263-8	5
1138	MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. <b>1985</b> , 335, 194-9	64

1137	Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [ <sup>3</sup> H]pargyline binding to monoamine oxidase. <b>1985</b> , 330, 337-42	44
1136	Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. <b>1985</b> , 358, 137-43	53
1135	Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA. <b>1985</b> , 342, 401-4	30
1134	Mechanism of MPTP toxicity: more answers, more questions. <b>1985</b> , 6, 375-378	48
1133	The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals. <b>1985</b> , 128, 25-33	88
1132	Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+. <b>1985</b> , 189, 225-30	29
1131	Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. <b>1985</b> , 110, 293-9	73
1130	Role of N-methyltransferases in the neurotoxicity associated with the metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and other 4-substituted pyridines present in the environment. <b>1986</b> , 35, 3359-63	50
1129	The effects of pyridinium salts, structurally related compounds of 1-methyl-4-phenylpyridinium ion (MPP+), on tyrosine hydroxylation in rat striatal tissue slices. <b>1986</b> , 397, 341-4	38
1128	High affinity binding sites for 1-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. <b>1986</b> , 129, 87-92	11
1127	Alterations in motor behaviour produced by the isomers of 3-PPP in the MPTP-treated marmoset. <b>1986</b> , 121, 123-8	21
1126	1-Methyl-4-phenylpyridine (MPP+): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. <b>1986</b> , 131, 199-209	36
1125	The basal ganglia and the locomotor regions. <b>1986</b> , 11, 47-63	297
1124	Synthetic analgesics and other phenylpiperidines: effects on uptake and storage of dopamine and other monoamines mouse forebrain tissue. <b>1986</b> , 39, 1765-77	5
1123	Interactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium species with synthetic dopamine-melanin. <b>1986</b> , 39, 1695-700	28
1122	Distribution of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in experimental animals studied by positron emission tomography and whole body autoradiography. <b>1986</b> , 38, 89-97	11
1121	Properties of <sup>3</sup> H-MPTP binding sites in human blood platelets. <b>1986</b> , 39, 1885-91	3
1120	"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates. <b>1986</b> , 39, 1375-82	24

1119	Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B. <b>1986</b> , 38, 1459-62	10
1118	1-Methyl-4-phenylpyridine (MPP+) induces oxidative stress in the rodent. <b>1986</b> , 38, 743-9	76
1117	The trained circling rat and in vivo electrochemistry: a behavioral model and a measurement method to study the dynamic role of dopamine in movement. <b>1986</b> , 473, 188-99	4
1116	Early and late effects of systemically administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on tyrosine hydroxylase activity in vitro and on tyrosine hydroxylation in tissue slices of mouse striatum. <b>1986</b> , 68, 245-8	31
1115	1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively destroys dopaminergic neurons in cultures of dissociated rat mesencephalic neurons. <b>1986</b> , 72, 215-20	72
1114	Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. <b>1986</b> , 231, 987-9	260
1113	Irreversible circling behavior induced by a single systemic administration of pepleomycin in mice. <b>1986</b> , 71, 89-94	2
1112	Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey. <b>1986</b> , 17, 1089-103	102
1111	BACTERIAL ARTHRITIS. <b>1986</b> , 328, 1163	
1110	Parkinson's disease and pesticides. <b>1986</b> , 2, 1163	45
1109	Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. <b>1986</b> , 2, 1162-3	12
1108	Pargyline and naltrexone fail to antagonize the gustatory avoidance response induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1986</b> , 18, 293-9	2
1107	The potential use of vitamin E and selenium in parkinsonism. <b>1986</b> , 20, 87-94	26
1106	Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of parkinsonism in monkeys. <b>1986</b> , 18, 817-22	116
1105	Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. <b>1986</b> , 63, 56-60	122
1104	Regional cerebral pharmacokinetics of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as examined by positron emission tomography in a baboon is altered by tranylcypromine. <b>1986</b> , 66, 205-9	17
1103	Histochemistry of MPTP oxidation in the rat brain: sites of synthesis of the parkinsonism-inducing toxin MPP+. <b>1986</b> , 65, 321-5	51
1102	Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [ <i>Macaca cynomolgus fascicularis</i> (Raffles)]. <b>1986</b> , 16, 561-71	37



1101	The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset. <b>1986</b> , 65, 79-83	36
1100	Mitochondria and the neurotoxicity of MPTP. <b>1986</b> , 7, 473-475	13
1099	Monoamine oxidase B, smoking, and Parkinson's disease. <b>1986</b> , 72, 265-72	55
1098	The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum. <b>1986</b> , 74, 111-9	11
1097	Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. <b>1986</b> , 25, 559-61	56
1096	Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat. <b>1986</b> , 25, 249-55	18
1095	Saccadic eye movement deficits in the MPTP monkey model of Parkinson's disease. <b>1986</b> , 383, 402-7	42
1094	Neurotoxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the cat. Tyrosine hydroxylase immunohistochemistry. <b>1986</b> , 373, 258-67	82
1093	A Parkinson-like neurologic deficit in primates is caused by a novel 4-substituted piperidine. <b>1986</b> , 368, 239-46	24
1092	MPTP causes a non-reversible depression of synaptic transmission in mouse neostriatal brain slice. <b>1986</b> , 368, 357-60	15
1091	Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. <b>1986</b> , 379, 286-93	90
1090	Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [ <sup>3</sup> H]spiperone binding. <b>1986</b> , 379, 294-9	228
1089	Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. <b>1986</b> , 376, 117-24	168
1088	Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: binding and biochemical studies. <b>1986</b> , 378, 320-4	12
1087	The mechanism of action of MPTP and MPP+ on endogenous dopamine release from the rat corpus striatum superfused in vitro. <b>1986</b> , 368, 134-40	48
1086	Early onset Parkinson's disease in Saskatchewan--environmental considerations for etiology. <b>1986</b> , 13, 312-6	78
1085	The age of onset of Parkinson's disease: etiological implications. <b>1986</b> , 13, 317-9	17
1084	Chemie von Herz und Hirn von außen betrachtet. <b>1986</b> , 34, 1057-1065	

1083	Quantification of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion in brain tissue by gas chromatography/mass spectrometry. <b>1986</b> , 13, 85-9	13
1082	Long-term follow-up of early dopa treatment in Parkinson's disease. <b>1986</b> , 19, 365-72	95
1081	Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. <b>1986</b> , 20, 449-55	299
1080	Saccade responses to dopamine in human MPTP-induced parkinsonism. <b>1986</b> , 20, 456-63	63
1079	Administration of MPTP to the common marmoset does not alter cortical cholinergic function. <b>1986</b> , 1, 129-34	13
1078	Clandestine drug synthesis. <b>1986</b> , 6, 41-74	46
1077	The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. <b>1986</b> , 6, 389-429	62
1076	L-dopa reverses the effects of MPP+ toxicity. <b>1986</b> , 88, 401-2	6
1075	The catecholamine uptake blocker nomifensine protects against MPTP-induced parkinsonism in monkeys. <b>1986</b> , 63, 216-20	33
1074	An autopsy case of dementia and parkinsonism with severe degeneration exclusively in the substantia nigra. <b>1986</b> , 70, 190-2	6
1073	Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. <b>1986</b> , 47, 1548-51	27
1072	Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. <b>1986</b> , 46, 1359-65	237
1071	Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. <b>1986</b> , 46, 1501-7	221
1070	The Neurotoxin l-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A Key to Parkinson's Disease?. <b>1986</b> , 3, 7-11	16
1069	Therapeutic progress--review XX. Drug treatment of Parkinson's disease. <b>1986</b> , 11, 229-36	
1068	Influence of monoamine oxidase inhibitors and a dopamine uptake blocker on the distribution of 11C-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 11C-MPTP, in the head of the rhesus monkey. <b>1986</b> , 74, 10-6	14
1067	Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice. <b>1986</b> , 128, 187-94	17
1066	The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine receptor binding site. <b>1986</b> , 65, 157-66	9

1065	Synthesis, function, and degradation of catecholamine neurotransmitters. <b>1986</b> , 65, 139-52	2
1064	Subcortical dementia. Neuropsychology, neuropsychiatry, and pathophysiology. <b>1986</b> , 149, 682-97	252
1063	Modification of Parkinson's disease by long-term levodopa treatment. <b>1986</b> , 43, 405-7	33
1062	Oxidative ionic metabolites of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation of electroreduction with physiological behavior. <b>1986</b> , 2, 107-13	21
1061	Melanin affinity of xenobiotics. <b>1986</b> , 91, 283-8	11
1060	Monoamine oxidase A and B from human liver and brain. <b>1987</b> , 142, 638-50	4
1059	Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. <b>1987</b> , 237, 913-6	426
1058	Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. <b>1987</b> , 14, 414-8	122
1057	The use of the MPTP-treated mouse as an animal model of parkinsonism. <b>1987</b> , 14, 436-40	39
1056	Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. <b>1987</b> , 84, 3521-5	94
1055	Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. <b>1987</b> , 84, 5995-9	41
1054	Regional and temporal effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine uptake sites in mouse brain. <b>1987</b> , 81, 261-71	14
1053	Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. <b>1987</b> , 77, 185-91	47
1052	Long-term effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine content in young and mature mice. <b>1987</b> , 77, 229-35	52
1051	Closer to Parkinson's disease: MPTP and the aging nervous system. <b>1987</b> , 8, 7-8	8
1050	Biochemical and behavioral correction of MPTP Parkinson-like syndrome by fetal cell transplantation. <b>1987</b> , 495, 623-40	82
1049	Injury of Catecholaminergic Neurons after Acute Exposure to MPTP. <b>1987</b> , 495, 730-731	12
1048	An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset. <b>1987</b> , 23, 1025-39	81

1047	The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) and its relevance to parkinson's disease. <b>1987</b> , 11, 359-73	74
1046	MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. <b>1987</b> , 136, 31-7	50
1045	MPTP fails to induce lipid peroxidation in vivo. <b>1987</b> , 36, 2251-3	27
1044	Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra. <b>1987</b> , 403, 43-51	180
1043	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. <b>1987</b> , 415, 293-9	97
1042	MPDP+ causes a non-reversible decrease in neostriatal synaptic transmission in mouse brain slice. <b>1987</b> , 425, 376-9	9
1041	Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. <b>1987</b> , 405, 26-38	196
1040	Localization of neurotensin receptors in the forebrain of the common marmoset and the effects of treatment with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1987</b> , 412, 244-53	29
1039	Effects on dopamine metabolism of MPTP and MPP+ infused through a push-pull cannula into the caudate nucleus of awake adult male rats. <b>1987</b> , 424, 49-57	5
1038	Actions of MPTP and MPP+ on synaptic transmission in guinea-pig hippocampal slices. <b>1987</b> , 96, 289-98	8
1037	Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. <b>1987</b> , 40, 1657-64	50
1036	Neuromelanin: a role in MPTP-induced neurotoxicity. <b>1987</b> , 40, 705-12	29
1035	Differential responsiveness to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum. <b>1987</b> , 40, 193-202	60
1034	Neurotoxins, parkinsonism and Parkinson's disease. <b>1987</b> , 32, 19-49	59
1033	Mechanism of oxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+). <b>1987</b> , 144, 692-8	16
1032	Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenyl-pyridinium ion. <b>1987</b> , 144, 957-64	32
1031	Evidence for the one-electron oxidation of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+). <b>1987</b> , 147, 354-60	10
1030	MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450buf1, P450db1) catalyzing debrisoquine 4-hydroxylation. <b>1987</b> , 148, 1144-50	127

1029	MPTP metabolites inhibit rat brain glutathione S-transferases. <b>1987</b> , 81, 159-64	10
1028	The toxicity of MPTP to dopamine neurons in culture is reduced at high concentrations. <b>1987</b> , 79, 65-72	34
1027	Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. <b>1987</b> , 21, 1-40	246
1026	Biochemistry of the neurotoxic action of MPTP: or how a faulty batch of "designer drug" led to parkinsonism in drug abusers. <b>1987</b> , 12, 266-270	43
1025	Intracerebral MPTP injections in the rat cause cell loss in the substantia nigra, ventral tegmental area and dorsal raphe. <b>1987</b> , 78, 145-50	21
1024	Difference in monoamine oxidase B activity between C57 black and albino NMRI mouse strains may explain differential effects of the neurotoxin MPTP. <b>1987</b> , 78, 253-8	22
1023	MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. <b>1987</b> , 75, 45-51	56
1022	Antioxidant therapy in Parkinson's disease. <b>1987</b> , 14, 483-7	30
1021	MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. <b>1987</b> , 14, 428-35	74
1020	Cerebral glucose and dopa metabolism in movement disorders. <b>1987</b> , 14, 448-51	13
1019	Histochemistry of MAO-A and MAO-B in the locus coeruleus of the Mongolian gerbil. <b>1987</b> , 70, 369-76	5
1018	Increased sensitivity of mice to tremorogenic agents following MPP+. <b>1987</b> , 92, 470-2	9
1017	The progression of idiopathic Parkinson's disease is not explained by age-related changes. Clinical and pathological comparisons with post-encephalitic parkinsonian syndrome. <b>1987</b> , 73, 195-201	30
1016	A fluorometric determination of N-methyl-4-phenylpyridinium ion, using high-performance liquid chromatography. <b>1987</b> , 162, 540-5	28
1015	Rheumatic manifestations of diseases associated with substance abuse. <b>1987</b> , 17, 90-111	18
1014	Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes. <b>1987</b> , 62, 105-16	25
1013	Neuromelanin and its possible protective and destructive properties. <b>1987</b> , 1, 133-6	29
1012	Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. <b>1987</b> , 48, 653-8	43

1011	Inhibition of monoamine oxidase by N-methylisoquinolinium ion. <b>1987</b> , 48, 709-12	25
1010	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. <b>1987</b> , 48, 1787-93	189
1009	Disposition of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice before and after monoamine oxidase and catecholamine reuptake inhibition. <b>1988</b> , 63, 75-80	7
1008	Studies on the acute and long-term changes in dopamine and noradrenaline metabolism in mouse brain following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1988</b> , 62, 213-22	15
1007	Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys. <b>1988</b> , 23, 86-9	10
1006	Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A model for parkinson's disease and its therapy. <b>1988</b> , 15, 1-15	8
1005	[No Parkinsonian syndrome following acute paraquat poisoning]. <b>1988</b> , 66, 1138-41	5
1004	Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+. <b>1988</b> , 74, 75-86	83
1003	Attenuation of MPTP-induced dopaminergic neurotoxicity by a serotonin uptake blocker. <b>1988</b> , 71, 85-90	14
1002	Studies with the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogs. <b>1988</b> , 49, 493-501	9
1001	Pyridine and other coal tar constituents as free radical-generating environmental neurotoxicants. <b>1988</b> , 84, 217-22	15
1000	Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. <b>1988</b> , 334, 345-8	1055
999	Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methyl-4-phenylpyridinium: cytochemical and morphological evidence. <b>1988</b> , 50, 1934-44	83
998	Synthesis and nuclear magnetic resonance spectroscopic, mass spectroscopic, and plasma amine oxidase inhibitory properties of analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1988</b> , 50, 1097-104	7
997	One-electron and two-electron reductions of 1-methyl-4-phenyl pyridinium (MPP+). <b>1988</b> , 242, 171-179	26
996	Selective decrease of immunoreactive tyrosine hydroxylase in nigrostriatum of adult male rats after N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. <b>1988</b> , 253, 251-8	3
995	Retroviral-mediated gene transfer. Applications in neurobiology. <b>1988</b> , 2, 155-82	3
994	Metabolism of [ <sup>14</sup> C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. <b>1988</b> , 1, 228-33	28

993	The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium. <b>1988</b> , 260, 789-97	83
992	Oxygen activation during the interaction between MPTP metabolites and synthetic neuromelanin--an ESR-spin trapping, optical, and oxidase electrode study. <b>1988</b> , 154, 781-8	10
991	Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP. <b>1988</b> , 146, 313-8	34
990	Covalent protein binding of a metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to mouse and monkey brain in vitro and in vivo. <b>1988</b> , 37, 4163-9	4
989	Dopaminergic nigrotectal projection in the rat. <b>1988</b> , 457, 165-8	22
988	Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. <b>1988</b> , 453, 227-34	30
987	Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): behavior and histology. <b>1988</b> , 474, 327-32	57
986	MPP+-induced increases in extracellular potassium ion activity in rat striatal slices suggest that consequences of MPP+ neurotoxicity are spread beyond dopaminergic terminals. <b>1988</b> , 475, 283-90	14
985	Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. <b>1988</b> , 444, 165-76	319
984	Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions. <b>1988</b> , 443, 101-16	31
983	1-Methyl-4-phenylpyridinium (MPP+) increases oxidation of cytochrome-b in rat striatal slices. <b>1988</b> , 443, 183-9	20
982	Acute electrophysiological and neurochemical effects of administration of MPTP in mice. <b>1988</b> , 27, 923-31	5
981	Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. <b>1988</b> , 86, 97-110	54
980	Suppression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mouse brain by piroheptine and trihexyphenidyl. <b>1988</b> , 83, 161-6	3
979	Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. <b>1988</b> , 515, 226-38	23
978	Discussion of the Paper. <b>1988</b> , 515, 237-237	
977	Aged Mice Show More Severe Motor Deficits and Morphological Changes following MPTP Treatment than Their Younger Counterparts. <b>1988</b> , 515, 421-423	1
976	MPTP effects on dopamine neurons. <b>1988</b> , 537, 451-61	5

975	Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. <b>1988</b> , 71, 461-8	33
974	Effect of 1-methyl-4-phenylpyridinium ion (MPP+) on catecholamine levels and activity of related enzymes in clonal rat pheochromocytoma PC12h cells. <b>1988</b> , 43, 1485-91	15
973	Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey. <b>1988</b> , 75, 370-6	25
972	An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. <b>1988</b> , 87, 178-82	191
971	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in <i>Macaca fascicularis</i> : which midbrain dopaminergic neurons are lost?. <b>1988</b> , 24, 161-74	179
970	Prevention of progression of Parkinson's disease with antioxidative therapy. <b>1988</b> , 12, 165-72	11
969	Effect of long-term administration of 1,2,3,4-tetrahydroisoquinoline (TIQ) on striatal dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) content in mice. <b>1988</b> , 92, 321-4	10
968	MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology. <b>1988</b> , 19, 153-61	41
967	The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. <b>1988</b> , 92, 228-33	69
966	Autoradiography of [ <sup>14</sup> C]paraquat or [ <sup>14</sup> C]diquat in frogs and mice: accumulation in neuromelanin. <b>1988</b> , 93, 1-6	94
965	Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors. <b>1988</b> , 27, 129-43	21
964	Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--I. Behavioural, neurochemical and histological characterization of the lesion. <b>1988</b> , 27, 117-28	41
963	Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. <b>1988</b> , 12, 345-54	72
962	Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. <b>1988</b> , 1, 24-36	104
961	Pulse Radiolysis. <b>1988</b> , 39-51	1
960	Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. <b>1988</b> , 111 ( Pt 1), 131-49	82
959	Autotransplantation of the superior cervical ganglion into the brain. A possible therapy for Parkinson's disease. <b>1988</b> , 68, 955-9	33
958	Accuracy in the clinical diagnosis of parkinsonian syndromes. <b>1988</b> , 64, 345-51	67



957	Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1988</b> , 85, 6172-6	56
956	Serotonin in involuntary movement disorders. <b>1988</b> , 42, 185-208	55
955	Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1988</b> , 78, 479-89	60
954	Recovery of dopaminergic fibers in striatum of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse is enhanced by grafts of adrenal medulla. <b>1988</b> , 78, 535-42	6
953	Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. <b>1988</b> , 78, 543-9	89
952	Chapter 32 Parkinson's disease—etiology and smoking. <b>1989</b> , 79, 329-333	5
951	Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?. <b>1989</b> , 52, 201-6	125
950	Clues to the mechanism underlying dopamine cell death in Parkinson's disease. <b>1989</b> , Suppl, 22-8	40
949	Increased dopamine receptor binding in duodenal mucosa of duodenal ulcer patients. <b>1989</b> , 34, 543-7	21
948	Interactions of manganese with human brain glutathione-S-transferase. <b>1989</b> , 57, 183-91	19
947	Astrocytes as a primary locus for the conversion MPTP into MPP+. <b>1989</b> , 76, 1-12	76
946	Gardening and young onset Parkinson disease. <b>1989</b> , 10, 465-6	
945	MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. <b>1989</b> , 1, 243-54	25
944	Platelet monoamine oxidase-B activity in Parkinson's disease. <b>1989</b> , 1, 255-61	23
943	Endogenous urinary monoamine oxidase inhibitor excretion in Parkinson's disease and other neurological disorders. <b>1989</b> , 1, 263-8	4
942	Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. <b>1989</b> , 10, 171-83	132
941	Depression of the hepatic cytochrome P-450 monooxygenase system by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1989</b> , 64, 107-10	7
940	Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1989</b> , 64, 276-81	17

939	Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. <b>1989</b> , 126, 19-22	53
938	MPTP-induced parkinsonism as a model for Parkinson's disease. <b>1989</b> , 126, 35-40	50
937	<sup>13</sup> C-labelling of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1989</b> , 27, 85-89	
936	The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1989</b> , 4, 53-74	22
935	HLA antigens in drug-induced parkinsonism. <b>1989</b> , 4, 121-8	20
934	MPP <sup>+</sup> -induced pathophysiology demonstrates advantages of neurotoxicology studies in brain slices. <b>1989</b> , 28, 51-7	6
933	<sup>6</sup> - <sup>18</sup> F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys. <b>1989</b> , 78, 69-80	39
932	Transplacental effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on brain dopaminergic neurons in the mouse. An immunohistochemical study. <b>1989</b> , 79, 279-85	11
931	Age-dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): correlation with monoamine oxidase-B. <b>1989</b> , 3, 308-14	25
930	Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. <b>1989</b> , 52, 1830-6	917
929	Selective visualization of rodent locus ceruleus by a radiolabeled N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analog. <b>1989</b> , 53, 459-64	3
928	Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment. <b>1989</b> , 53, 582-9	41
927	1-Methyl-4-phenylpyridinium uptake by human and rat striatal synaptosomes. <b>1989</b> , 52, 627-31	13
926	Clinical features and management of intoxication due to hallucinogenic drugs. <b>1989</b> , 4, 324-50	51
925	Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism by the catecholamine uptake inhibitor nomifensine: behavioral analysis in monkeys with partial striatal dopamine depletions. <b>1989</b> , 31, 219-30	15
924	Uptake of heterocyclic amines, Trp-P-1 and Trp-P-2, into clonal rat pheochromocytoma PC12h cells by dopamine uptake system. <b>1989</b> , 99, 317-22	14
923	S-methylation in motorneuron disease and Parkinson's disease. <b>1989</b> , 2, 356-7	52
922	Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice. <b>1989</b> , 106, 282-6	125

921	Histochemical localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine oxidation in the mouse brain. <b>1989</b> , 28, 189-99	26
920	N-methylisoquinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic l-amino acid decarboxylase and monoamine oxidase. <b>1989</b> , 15, 315-20	39
919	Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. <b>1989</b> , 28, 1089-97	42
918	Selective inhibition of complex I of the brain electron transport system by tetrahydroisoquinoline. <b>1989</b> , 162, 1541-5	27
917	Visualization of interleukin-2-like molecules in MPP(+)-lesioned rat brain. <b>1989</b> , 165, 1312-8	10
916	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits proton motive force in energized liver mitochondria. <b>1989</b> , 271, 217-22	7
915	Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. <b>1989</b> , 166, 373-80	47
914	Systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine reduces the release of [3H]dopamine from rat striatal slices. <b>1989</b> , 169, 147-52	1
913	Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. <b>1989</b> , 497, 250-9	32
912	MPTP treatment combined with ethanol or acetaldehyde selectively destroys dopaminergic neurons in mouse substantia nigra. <b>1989</b> , 501, 1-10	48
911	Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum. <b>1989</b> , 501, 11-22	36
910	Ultrastructural alterations induced by 1-methyl-4-phenylpyridinium (MPP+) in canine substantia nigra and rat mesencephalon in vitro. <b>1989</b> , 104, 235-40	10
909	Chemically induced Parkinson's disease. II: Intermediates in the oxidation and reduction reactions of the 1-methyl-4-phenyl-2,3-dihydropyridinium ion and its deprotonated form. <b>1989</b> , 158, 63-71	14
908	A sheep model for MPTP induced Parkinson-like symptoms. <b>1989</b> , 45, 1601-8	12
907	The role of environmental toxins in the etiology of Parkinson's disease. <b>1989</b> , 12, 49-54	236
906	Effects of MPP+ on the release of serotonin and 5-hydroxyindoleacetic acid from rat striatum in vivo. <b>1989</b> , 166, 49-55	29
905	Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <i>Toxicology Letters</i> , <b>1989</b> , 48, 121-49	4-4 108
904	Cyclosporin A, an immune suppressor, enhanced neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice. <b>1989</b> , 15, 249-54	9

903	Quantitative structure-activity relationship study on some dihydropteridine reductase inhibitors. <b>1989</b> , 2, 231-7	
902	Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. <b>1989</b> , 31, 1-79	155
901	Dopamine uptake sites in the striatum are distributed differentially in striosome and matrix compartments. <b>1989</b> , 86, 9020-4	65
900	Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. <b>1989</b> , 16, 310-4	102
899	Xenobiotic metabolism in Parkinson's disease. <b>1989</b> , 39, 883-7	108
898	Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. <b>1990</b> , 54, 1102-9	73
897	Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism. <b>1990</b> , 54, 1329-34	30
896	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A. <b>1990</b> , 55, 870-7	18
895	[3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion binding sites in mouse brain: pharmacological and biological characterization. <b>1990</b> , 54, 1905-10	15
894	Distribution of 1-(3H)-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (3H-MPTP) in the frog: uptake in neuromelanin. <b>1990</b> , 66, 252-8	6
893	MPTP-induced hypoactivity in mice: reversal by L-dopa. <b>1990</b> , 67, 295-301	65
892	Synthesis of some N-[pyridyl(phenyl)carbonylamino]-alkyl-1,2,3,6-tetrahydropyridines. <b>1990</b> , 27, 1041-1046	10
891	The hypothalamus in MPTP-induced parkinsonism. <b>1990</b> , 11, 367-72	15
890	MPTP induced parkinsonian syndrome: long term follow-up and neurophysiological study. <b>1990</b> , 11, 445-58	4
889	Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease. <b>1990</b> , 102, 295-300	57
888	Brain iron and ferritin in Parkinson's and Alzheimer's diseases. <b>1990</b> , 2, 327-40	340
887	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: characterization and age-dependent effects. <b>1990</b> , 5, 104-12	28
886	Pargyline-sensitive selective accumulation of a radiolabeled MPTP analog in the primate cerebral cortex and basal ganglia. <b>1990</b> , 5, 207-12	3

885	Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity. <b>1990</b> , 15, 425-9	29
884	Modifications of precentral cortex discharge and EMG activity in monkeys with MPTP-induced lesions of DA nigral neurons. <b>1990</b> , 80, 177-88	71
883	Studies on the uptake of N-methylisoquinolinium ion into rat striatal slices using high-performance liquid chromatography with fluorimetric detection. <b>1990</b> , 503, 189-95	10
882	Drug-induced parkinsonism and other movement disorders. <b>1990</b> , 17, 155-62	26
881	Autologous transplantation of the superior cervical ganglion into the brain of parkinsonian monkeys. <b>1990</b> , 72, 91-5	18
880	Cyclohexyladenosine reduces MPTP induced tremor in dogs. <b>1990</b> , 55, 125-8	4
879	Mso Prize for Young Pharmacologist: Striatal outputs and dyskinesia. <b>1990</b> , 4, 188-97	6
878	Extrapyramidal system, motor Ganglia and movement disorders. <b>1990</b> , 2, 145-64	7
877	Clustering of Parkinson's disease points to environmental etiology. <b>1990</b> , 45, 88-94	29
876	Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1990</b> , 17, 263-70	54
875	Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--III. Reversal by embryonic nigral dopamine grafts. <b>1990</b> , 37, 757-66	19
874	Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. <b>1990</b> , 119, 109-13	91
873	Evidence for retrograde axonal transport of MPP+ in the rat. <b>1990</b> , 118, 151-4	20
872	Similarities between neuronal Lewy bodies in parkinsonism and hepatic Mallory bodies in alcoholism. <b>1990</b> , 186, 473-8	9
871	Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. <b>1990</b> , 21, 181-7	60
870	"Designer drugs"--a current perspective. <b>1990</b> , 8, 733-41	25
869	The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism. <b>1990</b> , 22, 291-332	49
868	MPTP-induced parkinsonism. <b>1990</b> , 34, 107-14	27

867	Modulating role of dopamine on anesthetic requirements. <b>1990</b> , 186, 9-15	18
866	Potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium: selective toxicity of 1-methyl-4-(4'-acetamidophenyl)-pyridinium and 1-methyl-4-cyclohexylpyridinium for dopaminergic neurons in culture. <b>1990</b> , 108, 141-50	11
865	1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset. <b>1990</b> , 181, 97-103	7
864	Toxication of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and analogs by monoamine oxidase. A structure-reactivity relationship study. <b>1990</b> , 40, 783-92	21
863	Characterization of 1-methyl-4-[4'-amino]phenyl-1,2,3,6-tetrahydropyridine toxicity in the mouse. <b>1990</b> , 40, 901-6	2
862	Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. <b>1990</b> , 519, 266-76	211
861	Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. <b>1990</b> , 534, 25-36	94
860	Contrasting tissue factors predict heterogeneous striatal dopamine neurotoxicity after MPTP or methamphetamine treatment. <b>1990</b> , 534, 348-51	15
859	MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF). <b>1990</b> , 526, 156-60	139
858	Astroglial ablation prevents MPTP-induced nigrostriatal neuronal death. <b>1990</b> , 509, 55-61	56
857	Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. <b>1990</b> , 515, 57-63	100
856	The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. <b>1990</b> , 531, 95-104	63
855	Effects of MPTP on the fine structure of neurons in substantia nigra of dogs. <b>1990</b> , 512, 147-54	16
854	Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. <b>1990</b> , 528, 181-8	128
853	A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. <b>1990</b> , 525, 310-4	33
852	1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. <b>1990</b> , 170, 1049-55	310
851	Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson's disease. <b>1990</b> , 30, 301-2	21
850	The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. <b>1990</b> , 97, 273-93	140

849	Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. <b>1990</b> , 13, 296-302		276
848	Mechanisms of the inotropic actions of MPTP and MPP+ on isolated atria of rat. <b>1991</b> , 111, 49-57		3
847	Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite. <i>Toxicology Letters</i> , <b>1991</b> , 59, 117-23	4-4	51
846	Regional localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) uptake: mismatch between its uptake and neurotoxic sites. <b>1991</b> , 133, 137-40		8
845	Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa. <b>1991</b> , 123, 244-7		45
844	The role of environmental factors in neurodegenerative disorders. <b>1991</b> , 12, 75-9		3
843	Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. <b>1991</b> , 44, 591-605		193
842	Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. <b>1991</b> , 1, 228-48		50
841	Drug disposition in the mammalian eye and brain: a comparison of mechanisms. <b>1991</b> , 23, 133-246		15
840	A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function. <b>1991</b> , 42, 913-9		7
839	New directions in monoamine oxidase A and B selective inhibitors and substrates. <b>1991</b> , 41, 155-62		132
838	Inhibition of tryptophan hydroxylase by food-derived carcinogenic heterocyclic amines, 3-amino-1-methyl-5H-pyrido[4,3-b]indole and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole. <b>1991</b> , 41, 199-203		15
837	Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain?. <b>1991</b> , 41, 1099-105		84
836	Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. <b>1991</b> , 555, 239-44		22
835	Intracellular response of caudate neurons to variable frequency stimulation of motor cortical areas in dog. <b>1991</b> , 551, 116-25		2
834	The action of MPTP on synaptic transmission is affected by changes in Ca <sup>2+</sup> concentrations. <b>1991</b> , 541, 342-6		7
833	Apparent unilateral visual neglect in MPTP-hemiparkinsonian monkeys is due to delayed initiation of motion. <b>1991</b> , 541, 98-102		13
832	The nigrostriatal dopaminergic system in MPTP-treated mice shows more prominent recovery by syngeneic adrenal medullary graft than by allogeneic or xenogeneic graft. <b>1991</b> , 545, 191-8		64

831	Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. <b>1991</b> , 104, 203-8	192
830	Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. <b>1991</b> , 114 ( Pt 4), 1953-75	845
829	Accuracy of clinical diagnosis in parkinsonism--a prospective study. <b>1991</b> , 18, 275-8	479
828	MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. <b>1991</b> , 208, 273-86	259
827	Oxygen free radicals and Parkinson's disease. <b>1991</b> , 10, 161-9	250
826	Ageing and Parkinson's disease: substantia nigra regional selectivity. <b>1991</b> , 114 ( Pt 5), 2283-301	2513
825	Experimental reproduction of catecholamine-depleted states and parkinsonism □Theoretical and practical aspects. <b>1991</b> , 22, 296-306	2
824	Effect of stimulation of the nucleus entopeduncularis on neurons of thalamic motor nuclei under normal conditions and after injury of the nigrostriatal dopaminergic system by the neurotoxin mptp. <b>1991</b> , 23, 165-172	
823	Mechanism of accumulation of the 1-methyl-4-phenylpyridinium species into mouse brain synaptosomes. <b>1991</b> , 56, 1602-7	19
822	Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys. <b>1991</b> , 56, 1639-46	8
821	Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. <b>1991</b> , 57, 541-9	51
820	Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites. <b>1991</b> , 57, 981-90	12
819	Selective and nonselective effects of 1-methyl-4-phenylpyridinium on oxygen consumption in rat striatal and hippocampal slices. <b>1991</b> , 57, 1340-6	13
818	Oxidative stress as a cause of Parkinson's disease. <b>1991</b> , 136, 6-15	150
817	Metabolic biomarkers of Parkinson's disease. <b>1991</b> , 136, 19-23	12
816	A review of the pharmacology of selegiline. <b>1991</b> , 136, 44-59	87
815	Investigation of the possible dopaminergic toxicity of 1-methyl-3-phenyl-1,2,3,6-tetrahydropyridine, an isomer to the neurotoxin MPTP. <b>1991</b> , 69, 38-42	
814	Stereotaxic injection of GD1a ganglioside induces limited recovery of striatal dopaminergic system in MPTP-treated aging mice. <b>1991</b> , 28, 525-30	53



813	Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease. <b>1991</b> , 11, 261-7	3
812	Hereditary variation of liver enzymes involved with detoxification and neurodegenerative disease. <b>1991</b> , 14, 431-5	8
811	Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. <b>1991</b> , 14, 153-97	459
810	Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. <b>1991</b> , 3, 203-13	119
809	Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice. <b>1991</b> , 3, 109-25	13
808	The toxicity of mptp (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to <i>Periplaneta americana</i> l. and its effects on dopamine in the cerebral ganglia. <b>1991</b> , 32, 471-478	
807	Difficulties in using animal data to predict pharmacological response in man. <b>1991</b> , 15, 105-7	4
806	Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <b>1991</b> , 5, 405-17	7
805	Smoking and Parkinson's disease--a new perspective. <b>1991</b> , 9, 123-36	12
804	Nicotine, Parkinson's and Alzheimer's disease. <b>1992</b> , 3, 25-44	19
803	Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1992</b> , 89, 3859-63	128
802	1-Methyl-4-phenylpyridinium (MPP+) but not 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) serves as methyl donor for dopamine: a possible mechanism of action. <b>1992</b> , 5, 114-8	4
801	Efficacy of cyclophosphamide in sarcoid radiculomyelitis. <b>1992</b> , 55, 166-7	16
800	In vivo distribution of catecholamine reuptake sites in human brain gives clues to the physiopathology of MPTP-induced parkinsonism. <b>1992</b> , 55, 167	1
799	Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease. <b>1992</b> , 68, 634-7	29
798	Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. <b>1992</b> , 12, 1658-67	415
797	Hereditary Lewy-body parkinsonism and evidence for a genetic etiology of Parkinson's disease. <b>1992</b> , 2, 309-20	20
796	Trace dosages of the neurotoxins MPTP and MPP+ may affect brain dopamine in vivo. <b>1992</b> , 51, 389-96	2

795	Selective lesion of the nigrostriatal dopaminergic pathway by MPTP and acetaldehyde or diethylthiocarbamate. <b>1992</b> , 20 Suppl, 287S-293S	13
794	Mitochondrial function in neurodegeneration and ageing. <b>1992</b> , 275, 133-43	43
793	Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1992</b> , 12, 267-74	22
792	Striatal and non-striatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: the symptomatic versus the asymptomatic condition. <b>1992</b> , 20 Suppl, 295S-297S	20
791	Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset. <b>1992</b> , 142, 1-4	24
790	Is Parkinson's disease a mitochondrial disorder?. <b>1992</b> , 107, 29-33	65
789	Vitamin E. Neurochemistry and implications for neurodegeneration in Parkinson's disease. <b>1992</b> , 669, 97-109; discussion 109-10	27
788	Mitochondrial mechanisms of neurotoxicity. <b>1992</b> , 648, 28-36	15
787	The MPTP-treated mouse as a model of parkinsonism: how good is it?. <b>1992</b> , 20 Suppl, 299S-303S	61
786	Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. <b>1992</b> , 115 ( Pt 2), 333-42	301
785	Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease. <b>1992</b> , 575, 285-98	30
784	Characterization of a putatively vesicular binding site for [3H]MPP+ in mouse striatal membranes. <b>1992</b> , 571, 354-7	15
783	Disappearance of circadian rhythms in Parkinson's disease model induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in dogs. <b>1992</b> , 580, 92-9	31
782	Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons. <b>1992</b> , 590, 311-5	9
781	Spontaneous recovery of MPTP-damaged catecholamine systems in goldfish brain areas. <b>1992</b> , 585, 128-34	11
780	Do NMDA receptor antagonists protect against MPTP-toxicity? Biochemical and immunocytochemical analyses in black mice. <b>1992</b> , 592, 74-83	70
779	Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. <b>1992</b> , 212, 247-52	11
778	Protective and Preventive Therapeutic Strategies: Monoamine Oxidase Inhibitors. <b>1992</b> , 10, 541-552	3

777	A Brief History of Parkinsonism. <b>1992</b> , 10, 301-316	20
776	What Process Causes Nigral Cell Death in Parkinson's Disease?. <b>1992</b> , 10, 387-403	23
775	In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. <b>1992</b> , 10, 169-72	78
774	Effect of amiridine on MPTP-induced Parkinson's syndrome in monkeys. <b>1992</b> , 114, 1638-1641	
773	1-Methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells is enhanced by preventing glycolysis. <b>1992</b> , 58, 1052-9	36
772	N-methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study. <b>1992</b> , 59, 395-400	97
771	Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. <b>1992</b> , 58, 642-8	236
770	Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. <b>1992</b> , 58, 1997-2004	46
769	Molecular properties of monoamine oxidases A and B. <b>1992</b> , 106 Suppl, S1-5	16
768	Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. <b>1992</b> , 88, 117-30	54
767	Localization of MPP <sup>+</sup> binding sites in the brain of various mammalian species. <b>1992</b> , 4, 181-90	4
766	Increased binding of 3H-L-deprenyl in spinal cords from patients with amyotrophic lateral sclerosis as demonstrated by autoradiography. <b>1992</b> , 89, 111-22	29
765	The use of thalamotomy in the treatment of levodopa-induced dyskinesia. <b>1992</b> , 114, 77-117	43
764	Management of early inflammatory arthritis. Genetic factors predicting persistent disease: the role of defective enzyme systems. <b>1992</b> , 6, 337-50	5
763	Debrisoquine hydroxylation in Parkinson's disease. <b>1992</b> , 86, 159-64	24
762	Fifteen years of research of bioactive alkaloids. <b>1992</b> , 12, 1-26	13
761	Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. <b>1992</b> , 32 Suppl, S94-100	226
760	Association of a monoamine oxidase B allele with Parkinson's disease. <b>1993</b> , 33, 368-72	149

759	Serotonergic sprouting in primate MPTP-induced hemiparkinsonism. <b>1993</b> , 96, 100-6		65
758	Maladie de Parkinson: mécanismes physiopathologiques et effets du piribédil. <i>Journal of Neurology</i> , <b>1993</b> , 240, S2-S8	5.5	2
757	Dégeneration des voies dopaminergiques et altérations des fonctions cognitives et motrices. <i>Journal of Neurology</i> , <b>1993</b> , 240, S9-S12	5.5	2
756	The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. <b>1993</b> , 5, 1029-34		48
755	Protection against acute MPTP-induced dopamine depletion in mice by adenosine A1 agonist. <b>1993</b> , 60, 768-71		30
754	Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH <sub>2</sub> -MPTP): a comparative study with 2'-CH <sub>3</sub> -MPTP and MPTP. <b>1993</b> , 60, 1167-70		32
753	1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol depletes catecholamines in rat brain. <b>1993</b> , 61, 2199-206		17
752	The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates. <b>1993</b> , 348, 586-92		66
751	Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. <b>1993</b> , 6, 45-52		29
750	Platelet monoamine oxidase B activity in Parkinson's disease: a re-evaluation. <b>1993</b> , 5, 1-4		16
749	Effect of acetyl-L-carnitine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. <b>1993</b> , 45, 2170-2		7
748	Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. <b>1993</b> , 612, 221-30		76
747	Selective MPP <sup>+</sup> uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. <b>1993</b> , 109, 411-4		50
746	Parkinson's disease: past, present, and future. <b>1993</b> , 9, 1-12		31
745	Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. <b>1993</b> , 55, 147-65		57
744	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) effects on enkephalinergic neurons in various regions of mouse brain. <b>1993</b> , 22, 175-82		5
743	Intracerebral grafting of catecholamine producing cells and reconstruction of disturbed brain function. <b>1993</b> , 16, 157-72		20
742	Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. <b>1993</b> , 53, 169-78		91

741	3-Acetylpyridine neurotoxicity to the nigrostriatal dopamine system in mice. <b>1993</b> , 161, 211-4	3
740	MPTP neurotoxicity to cerebellar Purkinje cells in mice. <b>1993</b> , 150, 49-52	28
739	Genetics: Animal and Human Cytochrome P450 Polymorphisms. <b>1993</b> , 433-446	1
738	Hypersusceptibility to chemicals: risk factors for neurological disease?. <b>1993</b> , 56, 943-6	5
737	Movement disorders: therapeutic role of vitamin E. <b>1993</b> , 9, 337-47	4
736	6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys. <b>1993</b> , 4, 27-38	15
735	Opioids. <b>1993</b> , 11, 503-522	33
734	Movement Disorders. <b>1993</b> , 11, 625-638	22
733	Mitochondrial dysfunction in neurodegenerative disorders and aging. <b>1994</b> , 227-244	12
732	[125I]CGP 42112 reveals a non-angiotensin II binding site in 1-methyl-4-phenylpyridine (MPP+)-induced brain injury. <b>1994</b> , 14, 99-104	16
731	Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. <b>1994</b> , 8, 215-21	59
730	Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice. <b>1994</b> , 97, 197-209	21
729	No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys. <b>1994</b> , 17, 115-24	10
728	Neurotrophin-4/5 is a survival factor for embryonic midbrain dopaminergic neurons in enriched cultures. <b>1994</b> , 37, 144-54	101
727	Meperidine and reversible parkinsonism. <b>1994</b> , 9, 115-6	10
726	An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. <b>1994</b> , 35, 204-10	176
725	Medium latency stretch reflexes in young-onset Parkinson's disease and MPTP-induced parkinsonism. <b>1994</b> , 123, 52-8	14
724	Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. <b>1994</b> , 44, 141-61	44

723	Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. <b>1994</b> , 63, 47-56	100
722	Reduction of 1-methyl 1,2,3,4-tetrahydroisoquinoline level in substantia nigra of the aged rat. <b>1994</b> , 638, 334-6	24
721	Studies on the pathogenesis of Parkinson's disease in Japan. <b>1994</b> , 19, 105-21	3
720	Glutamatergic drugs in Parkinson's disease. <b>1994</b> , 55, 2067-75	38
719	Muscle respiratory chain enzyme activities in parkinson's disease and in multisystem extrapyramidal disorders with parkinsonism as the main clinical feature. <b>1994</b> , 19 Suppl 1, 155-61	4
718	Comparison of brain dopamine depletion induced by low-dose 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in young and aged rats. <b>1994</b> , 20, 27-33	9
717	Effects of designer drugs on the chicken embryo and 1-day-old chicken. <b>1994</b> , 34, 143-50	24
716	Electrophysiological investigation of thalamic neuronal mechanisms of motor disorders in parkinsonism: an influence of D2ergic transmission blockade on excitation and inhibition of relay neurons in motor thalamic nuclei of cat. <b>1994</b> , 62, 771-81	12
715	Potential of Neuroprotective Therapy in Parkinson's Disease. <b>1994</b> , 1, 45-56	14
714	Bioactivation by S-Adenosylation, S-Methylation, or N-Methylation. <b>1994</b> , 27, 449-477	5
713	Disease Clusters: Paradoxes of Perception and Public Health. <b>1995</b> , 1, 289-290	
712	Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. <b>1995</b> , 37, 733-9; discussion 739-41	107
711	Novel sites of action for deprenyl in MPTP-parkinsonism: metabolite-mediated protection against striatal neurotoxicity and suppression of MPTP-induced increase of dopamine turnover in C57BL mice. <b>1995</b> , 106, 155-71	2
710	Immunotoxin-mediated conditional disruption of specific neurons in transgenic mice. <b>1995</b> , 92, 1132-6	75
709	Heavy metals and the etiology of Parkinson's disease and other movement disorders. <b>1995</b> , 97, 3-9	79
708	Short and long-term changes in cerebral [ <sup>14</sup> C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity. <b>1995</b> , 101, 65-82	16
707	Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice. <b>1995</b> , 102, 19-34	18
706	Short-term manganese pretreatment partially protects against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. <b>1995</b> , 20, 1217-23	21

705	Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. <b>1995</b> , 291, 407-15	24
704	Dimethylthiourea prevents MPTP-induced decrease in [3H]dopamine uptake in rat striatal slices. <b>1995</b> , 671, 321-4	7
703	Methyl-beta-carbolinium analogs of MPP+ cause nigrostriatal toxicity after substantia nigra injections in rats. <b>1995</b> , 675, 279-88	51
702	MPTP- and MPP(+)-induced effects on body temperature exhibit age- and strain-dependence in mice. <b>1995</b> , 688, 161-70	45
701	Selective acid vulnerability of dopaminergic neurons and its recovery by brain-derived neurotrophic factor. <b>1995</b> , 704, 175-83	17
700	The History, Theory, and Present Status of Brain Transplantation. <b>1995</b> , 6, 113-125	13
699	Intrastriatal Cografts of Autologous Adrenal Medulla and Sural Nerve in MPTP-Induced Parkinsonian Macaques: Behavioral and Anatomical Assessment. <b>1995</b> , 4, 27-38	22
698	Neurochemical, neuroprotective and neurorescue effects of aliphatic N-methylpropargylamines; new MAO-B inhibitors without amphetamine-like properties. <b>1995</b> , 106, 113-21	15
697	Xenobiotic metabolism in brain. <b>1995</b> , 27, 419-48	46
696	Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. <b>1995</b> , 1271, 265-74	122
695	Chemical anatomy of primate basal ganglia. <b>1995</b> , 46, 131-197	121
694	Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys. <b>1995</b> , 4, 81-5	9
693	Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. <b>1995</b> , 277, 235-41	24
692	Inhibition of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolic activity of porcine FAD-containing monooxygenase by selective monoamine oxidase-B inhibitors. <b>1995</b> , 358, 145-8	6
691	Selegiline. <b>1995</b> , 4, 230-246	11
690	Mass spectrometry in Parkinson's disease. <b>1995</b> , 241-242, 223-250	
689	Intrastriatal cografts of autologous adrenal medulla and sural nerve in MPTP-induced parkinsonian macaques: behavioral and anatomical assessment. <b>1995</b> , 4, 27-38	15
688	Altered brain sensitivity to ethanol in mice after MPTP treatment. <b>1995</b> , 12, 127-30	8

687	A quantitative study of cell death in the substantia nigra following a mechanical lesion of the medial forebrain bundle. <b>1995</b> , 64, 219-27	43
686	Treatment of early Parkinson's disease: are complicated strategies justified?. <b>1996</b> , 71, 659-70	12
685	Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin. <b>1996</b> , 28, 41-9	27
684	Potential role of environmental genotoxic agents in diabetes mellitus and neurodegenerative diseases. <b>1996</b> , 51, 1585-91	20
683	Heterogeneity of monoaminergic vesicular carriers: pharmacological evidence using MPP+ as a marker. <b>1996</b> , 59, 1703-10	1
682	Gastric Helicobacter pylori infection as a cause of idiopathic Parkinson disease and non-arteric anterior optic ischemic neuropathy. <b>1996</b> , 47, 413-4	44
681	Variability in susceptibility of the nervous system to toxic insult. <b>1996</b> , 2, 131-3	
680	[3H]dihydrorotenone binding to NADH: ubiquinone reductase (complex I) of the electron transport chain: an autoradiographic study. <b>1996</b> , 16, 3807-16	84
679	Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. <b>1996</b> , 93, 5166-71	362
678	Neurological disease. <b>1997</b> , 38, 557-80	6
677	Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. <b>1996</b> , 274, 1197-9	610
676	Is levodopa toxic?. <b>1996</b> , 47, S184-95	101
675	MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. <b>1996</b> , 715, 1-8	86
674	Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. <b>1996</b> , 103, 987-1041	422
673	Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. <b>1996</b> , 103, 1077-81	64
672	GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism. <b>1996</b> , 21, 245-50	14
671	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. <b>1996</b> , 741, 185-96	93
670	Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. <b>1996</b> , 43, 55-62	51



669	Endogenous alkaloids in man. XXVI. Determination of the dopaminergic neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) in biological samples using gas chromatography with selected ion monitoring. <b>1996</b> , 687, 337-48	14
668	Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. <b>1996</b> , 16, 450-61	76
667	Illumination of therapeutics by toxicology: a personal view. <b>1996</b> , 23, 1010-3	
666	Mechanisms of Drug Interactions. <b>1996</b> ,	1
665	Cytochrome P450-dependent biotransformation of drugs and other xenobiotic substrates in neural tissue. <b>1997</b> , 29, 1079-105	23
664	Parkinson's Disease. <b>1997</b> , 216-245	6
663	Handbook of Neuropsychology and Aging. <b>1997</b> ,	12
662	PET studies of functional compensation in a primate model of Parkinson's disease. <b>1997</b> , 8, 2727-33	42
661	Levodopa-Induced Neurotoxicity. <b>1997</b> , 8, 376-393	46
660	Isoquinoline neurotoxins in the brain and Parkinson's disease. <b>1997</b> , 29, 99-111	211
659	Suspected MPTP-induced parkinsonism. <b>1997</b> , 4, 366-70	2
658	Species differences in the role of excitatory amino acids in experimental parkinsonism. <b>1997</b> , 21, 401-15	43
657	Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. <b>1997</b> , 234, 123-6	37
656	Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey ( <i>Cercopithecus aethiops sabaesus</i> ). <b>1997</b> , 81, 745-55	69
655	Role of heat shock proteins in MPTP-induced neurotoxicity. <b>1997</b> , 825, 167-78	11
654	Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. <b>1997</b> , 81, 226-31	24
653	Dopamine/glutamate interactions in Parkinson's disease. <b>1997</b> , 21, 393-400	110
652	Systemic administration of MPTP induces thalamic neuronal degeneration in mice. <b>1997</b> , 759, 9-17	75

651	Neurotoxic effects of papaverine, tetrahydropapaverine and dimethoxyphenylethylamine on dopaminergic neurons in ventral mesencephalic-striatal co-culture. <b>1997</b> , 754, 260-8	22
650	A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. <b>1997</b> , 766, 107-12	141
649	Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. <b>1997</b> , 771, 133-41	31
648	Dimethoxyphenylethylamine and tetrahydropapaverine are toxic to the nigrostriatal system. <b>1997</b> , 773, 108-16	21
647	Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease. <b>1997</b> , 22, 113-21	23
646	Vesicular neurotransmitter transporters. Potential sites for the regulation of synaptic function. <b>1997</b> , 15, 165-91	63
645	Increased plasma bilirubin in Parkinson patients on L-dopa: evidence against the free radical hypothesis?. <b>1997</b> , 18, 69-72	17
644	Cytotoxicity of endogenous isoquinolines to human dopaminergic neuroblastoma SH-SY5Y cells. <b>1997</b> , 104, 59-66	32
643	Regioselective deuterium labeling of 1,4-disubstituted-1,2,3,6-tetrahydropyridines. <b>1997</b> , 39, 409-423	6
642	Striatal and urinary DOPAC/DA ratio may indicate a long-lasting DA release enhancement by MPP+ and MPTP. <b>1998</b> , 23, 127-34	4
641	Zonisamide: Pharmacology and Clinical Efficacy in Epilepsy. <b>1998</b> , 4, 341-360	38
640	Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. <b>1998</b> , 22, 789-813	39
639	Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. <b>1998</b> , 806, 292-6	15
638	Differences in pre- and post-synaptic sensitivity to apomorphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity. <b>1998</b> , 353, 1-4	14
637	MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. <b>1998</b> , 24, 76-84	75
636	Welcome news about levodopa, but uncertainty remains. <b>1998</b> , 43, 551-4	26
635	Environmental MPTP as a factor in the aetiology of Parkinson's disease?. <b>1998</b> , 105, 1265-9	3
634	Pharmacological characterisation of dopamine overflow in the striatum of the normal and MPTP-treated common marmoset, studied in vivo using fast cyclic voltammetry, nomifensine and sulpiride. <b>1998</b> , 85, 201-9	16

- 633 Towards a dynamic approach of experimental parkinsonism. **1998**, 22, 1317-1329 2
- 632 Orphan neurones and amine excess: the functional neuropathology of Parkinsonism and neuropsychiatric disease. **1998**, 27, 177-242 17
- 631 Free radicals and the pathobiology of brain dopamine systems. **1998**, 32, 117-31 432
- 630 Dipyridamole potentiates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced experimental Parkinsonism in mice. **1998**, 4, 43-50 6
- 629 Protective Effects of the Antiparkinsonian Drugs Talipexole and Pramipexole against 1-Methyl-4-phenylpyridinium-Induced Apoptotic Death in Human Neuroblastoma SH-SY5Y Cells. **1998**, 54, 1046-1054 164
- 628 The Possible Role of an Active Metabolite Derived from the Neuroleptic Agent Haloperidol in Drug-Induced Parkinsonism. **1998**, 17, 27-38 4
- 627 MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. **1998**, 152, 214-20 31
- 626 MPTP-Induced Modulation of Neurotransmitters in SH-SY5Y Human Neuroblastoma Cells. **1998**, 17, 677-701 2
- 625 Experimental models of Parkinson's disease: from the static to the dynamic. **1998**, 9, 71-90 63
- 624 Brain histamine in pathophysiological conditions and brain diseases. **1998**, 243-253
- 623 Apoptosis in Degenerative Diseases of the Basal Ganglia. **1998**, 4, 301-311 3
- 622 Ablative surgery and deep brain stimulation for Parkinson's disease. **1998**, 43, 989-1013; discussion 1013-5 190
- 621 Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. **1998**, 78, 23-9 21
- 620 Genetics, drugs and environmental factors in Parkinson's disease. A case-control study. **1999**, 57, 347-55 33
- 619 Genetic Engineering for Parkinson's Disease. **1999**, 437-XII 1
- 618 Pathogenesis and preclinical course of Parkinson's disease. **1999**, 56, 31-74 31
- 617 Preclinical models of Parkinson's disease. **2001**, Chapter 9, Unit9.4 20
- 616 Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. **1999**, 147, 90-5 183

615	Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists. <b>1999</b> , 106, 283-300	27
614	Nocturnal sleep structure and temperature slope in MPTP treated monkeys. <b>1999</b> , 106, 1125-34	48
613	Oxidative stress induced by MPTP and MPP(+): selective vulnerability of cultured mouse astrocytes. <b>1999</b> , 836, 237-44	36
612	MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study. <b>1999</b> , 21, 169-75	76
611	1-Methyl-4-phenylpyridinium ion (MPP+) selectively inhibits the replication of mitochondrial DNA. <b>1999</b> , 259, 412-8	20
610	Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. <b>1999</b> , 46, 598-605	791
609	Animal models of tremor. <b>1999</b> , 14, 557-71	148
608	Effect of highly halogenated $\beta$ -carbolines on dopaminergic cells in culture and on mitochondrial respiration. <b>1999</b> , 46, 51-56	20
607	Tracers for imaging melanin with positron emission tomography. <b>1999</b> , 31, 5-12	5
606	Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. <b>1999</b> , 33, 282-8	10
605	Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. <b>1999</b> , 53, 22-3	149
604	MPP(+) and glutamate in the degeneration of nigral dopaminergic neurons. <b>1999</b> , 5, 209-15	3
603	Pesticides and Parkinson's disease. <b>1999</b> , 53, 122-30	149
602	A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. <b>1999</b> , 275, 215-8	28
601	Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. <b>1999</b> , 72, 183-94	37
600	The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies. <b>2000</b> , 127, 267-97	11
599	Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons. <b>2000</b> , 59, 126-135	25
598	Functional anatomy of movement disorders. <b>2000</b> , 196 ( Pt 4), 519-25	77

597	The D-loop structure of human mtDNA is destabilized directly by 1-methyl-4-phenylpyridinium ion (MPP+), a parkinsonism-causing toxin. <b>2000</b> , 267, 200-6	66
596	Bromal-derived tetrahydro-beta-carbolines as neurotoxic agents: chemistry, impairment of the dopamine metabolism, and inhibitory effects on mitochondrial respiration. <b>2000</b> , 8, 1467-78	32
595	Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. <b>2000</b> , 153, 123-41	43
594	Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. <b>2000</b> , 96, 71-6	126
593	DNA damage in brain mitochondria caused by aging and MPTP treatment. <b>2000</b> , 885, 45-52	68
592	Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. <i>Journal of Neurology</i> , <b>2000</b> , 247 Suppl 2, 1182-94	5.5 58
591	Restoration and putative protection in Parkinsonism. <b>2000</b> , 2, 251-92	6
590	Neurofilament-rich intraneuronal inclusions exacerbate neurodegenerative sequelae of brain trauma in NFH/LacZ transgenic mice. <b>2000</b> , 165, 77-89	18
589	The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. <b>2000</b> , 166, 235-45	84
588	Aboulia: neurobehavioural dysfunction of dopaminergic system?. <b>2000</b> , 54, 523-30	13
587	Preliminary evaluation of an in vitro test for assessment of excitotoxicity by measurement of early gene (c-fos mRNA) levels. <b>2000</b> , 14, 447-58	8
586	The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. <b>2000</b> , 39, 1016-20	29
585	Metabolic defects caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and by HPTP (the tetrahydropyridinyl analog of haloperidol), in rats. <b>2000</b> , 66, 1949-54	4
584	Basal ganglia neurotoxins. <b>2000</b> , 18, 665-80	42
583	Pathophysiological Considerations in Basal Ganglia Surgery: Role of the Basal Ganglia in Hypokinetic and Hyperkinetic Movement Disorders. <b>2000</b> , 15, 31-57	8
582	Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. <b>2001</b> , 168, 171-82	41
581	Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. <b>2001</b> , 106, 589-601	263
580	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. <b>2001</b> , 65, 135-72	933

579	Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. <b>2001</b> , 125, 109-25	330
578	Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia. <b>2001</b> , 22, 13-42	67
577	Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice. <b>2001</b> , 8, 85-90	10
576	Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. <b>2001</b> , 31, 161-70	28
575	Experimental parkinsonism in primates. <b>2001</b> , 77, 91-7	9
574	Neurochemical findings in the MPTP model of Parkinson's disease. <b>2001</b> , 108, 1263-82	221
573	Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. <b>2001</b> , 108, 985-1009	102
572	Characterization and localization of cytochrome P450 mediated metabolism of MPTP to nor-MPTP in mouse brain: relevance to Parkinson's disease. <b>2001</b> , 3, 369-80	7
571	The endogenous amine 1-methyl-1,2,3,4- tetrahydroisoquinoline prevents the inhibition of complex I of the respiratory chain produced by MPP(+). <b>2000</b> , 75, 65-71	22
570	Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism. <b>2001</b> , 76, 1010-21	201
569	The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. <b>2001</b> , 76, 1265-74	358
568	Neurotoxicity of MPTP. <b>2001</b> , 21, 323-32	28
567	Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes. <b>2001</b> , 432, 184-96	46
566	New strategies for the treatment of Parkinson's disease hold considerable promise for the future management of neurodegenerative disorders. <b>2001</b> , 2, 193-207	27
565	1-Methyl-4-phenyl-pyridinium increases S-adenosyl-L-methionine dependent phospholipid methylation. <b>2001</b> , 70, 105-14	15
564	Mitochondria make a come back. <b>2001</b> , 49, 3-26	108
563	SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. <b>2001</b> , 892, 241-7	33
562	Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. <b>2001</b> , 919, 106-14	160

561	Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. <b>2001</b> , 417, 59-67		62
560	Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptotic cell death in dopaminergic cells. <b>2001</b> , 31, 1473-85		145
559	Mitochondrial dysfunction in neurodegenerative disorders and ageing. <b>2001</b> , 487, 229-51		23
558	D1 dopamine receptors. <b>2001</b> , 48, 65-139		24
557	The role of nitric oxide in Parkinson's disease. <b>2001</b> , 62, 113-36		4
556	Pharmacological approaches to disease-modifying therapies in Parkinson's disease. <b>2002</b> , 2, 819-34		7
555	Parkinson's disease. <b>2002</b> , 53, 283-314		6
554	Drug-induced parkinsonism. <b>2002</b> , 8, 363-70		28
553	Mort neuronale dans les modèles expérimentaux de la maladie de Parkinson. <b>2002</b> , 18, 457-466		3
552	Animal Models for Schizophrenia. 565-580		1
551	Neuroprotective gene therapy for Parkinson's disease. <b>2002</b> , 2, 451-83		20
550	Environmental risk factors of young onset Parkinson's disease: a case-control study. <i>Clinical Neurology and Neurosurgery</i> , <b>2002</b> , 104, 328-33	2	65
549	Dopamine in the CNS II. <b>2002</b> ,		1
548	Tremor in Parkinson's disease. <b>2002</b> , 8, 223-34		25
547	Occupational and environmental risk factors for Parkinson's disease. <b>2002</b> , 8, 297-309		110
546	Mitochondrial involvement in Parkinson's disease. <b>2002</b> , 40, 533-41		163
545	Toxin-induced mitochondrial dysfunction. <b>2002</b> , 53, 243-79		15
544	Biochemical and pharmacological characterization of 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline: a biologically relevant neurotoxin?. <b>2002</b> , 442, 1-16		45

543	Protective effect of melatonin in a chronic experimental model of Parkinson's disease. <b>2002</b> , 943, 163-73	126
542	Differential vulnerability of snake species to MPTP: a behavioral and biochemical comparison in ratsnakes ( <i>Elaphe</i> ) and watersnakes ( <i>Nerodia</i> ). <b>2002</b> , 24, 227-33	2
541	Amine-related neurotoxins in Parkinson's disease: past, present, and future. <b>2002</b> , 24, 565-9	32
540	Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease. <b>2002</b> , 24, 579-91	87
539	MPTP: insights into parkinsonian neurodegeneration. <b>2002</b> , 24, 607-20	111
538	Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. <b>2002</b> , 17, 887-901	48
537	Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. <b>2000</b> , 75, 521-31	54
536	Inhibition of brain mitochondrial respiration by dopamine: involvement of H <sub>2</sub> O <sub>2</sub> and hydroxyl radicals but not glutathione-protein-mixed disulfides. <b>2002</b> , 82, 66-74	52
535	1-Methyl-4-phenylpyridinium ion, a toxin that can cause parkinsonism, alters branched structures of DNA. <b>2002</b> , 82, 30-7	7
534	1-Methyl-4-phenylpyridinium (MPP <sup>+</sup> )-induced functional run-down of GABA(A) receptor-mediated currents in acutely dissociated dopaminergic neurons. <b>2002</b> , 83, 87-99	12
533	Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. <b>1994</b> , 63, 640-8	96
532	Studies on the characterization of the inhibitory mechanism of 4'-alkylated 1-methyl-4-phenylpyridinium and phenylpyridine analogues in mitochondria and electron transport particles. <b>1994</b> , 63, 655-61	31
531	Protection and potentiation of 1-methyl-4-phenylpyridinium-induced toxicity by cytochrome P450 inhibitors and inducer may be due to the altered uptake of the toxin. <b>1995</b> , 64, 1203-8	9
530	Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. <b>1996</b> , 66, 1174-81	52
529	Neuroprotective effect of the iron chelator desferrioxamine against MPP <sup>+</sup> toxicity on striatal dopaminergic terminals. <b>1997</b> , 68, 732-8	33
528	1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo) and related derivatives: chemistry and biochemical effects on catecholamine biosynthesis. <b>2002</b> , 10, 2207-14	22
527	Oxidative Stress and Parkinson's Disease. <b>2002</b> , 593-608	2
526	Effect of MPTP on Dopamine metabolism in Ames dwarf mice. <b>2002</b> , 27, 457-64	8



525	Physiological and anatomical link between Parkinson-like disease and REM sleep behavior disorder. <b>2003</b> , 27, 137-52	62
524	Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment. <b>2003</b> , 5, 95-110	18
523	Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. <b>2003</b> , 167, 449-50	2
522	Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate. <b>2003</b> , 110, 871-83	2
521	Effects of monoamine oxidase inhibitors on the diethyldithiocarbamate-induced enhancement of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity in C57BL/6 mice. <b>2003</b> , 110, 859-69	5
520	Rapid reduction of ATP synthesis and lack of free radical formation by MPP+ in rat brain synaptosomes and mitochondria. <b>2003</b> , 975, 214-21	29
519	References. <b>2003</b> , 271-281	
518	Dependence on electron transport chain function and intracellular signaling of genomic responses in SH-SY5Y cells to the mitochondrial neurotoxin MPP(+). <b>2003</b> , 181, 25-38	14
517	Primate models of Parkinson's disease. <b>2003</b> , 183, 258-62	23
516	Dieldrin induces apoptosis by promoting caspase-3-dependent proteolytic cleavage of protein kinase Cdelta in dopaminergic cells: relevance to oxidative stress and dopaminergic degeneration. <b>2003</b> , 119, 945-64	138
515	Using cDNA microarray to assess Parkinson's disease models and the effects of neuroprotective drugs. <b>2003</b> , 24, 184-91	66
514	Parkinson's disease: mechanisms and models. <b>2003</b> , 39, 889-909	3874
513	The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. <b>2003</b> , 9, 131-7	89
512	Disease model: Parkinson's disease. <b>2003</b> , 9, 360-5	135
511	Neuroprotective strategies in Parkinson's disease : an update on progress. <b>2003</b> , 17, 729-62	166
510	Inhibitory effects of antiparkinsonian drugs and caspase inhibitors in a parkinsonian flatworm model. <b>2003</b> , 92, 137-42	16
509	Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?. <b>2004</b> , 279, 19936-47	207
508	Opioids. <b>2004</b> , 43-103	1

507	CNS dopamine oxidation and catechol-O-methyltransferase: Importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease. <b>2004</b> , 13, 343	2
506	Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. <b>2004</b> , 91, 285-98	42
505	MPP+: mechanism for its toxicity in cerebellar granule cells. <b>2004</b> , 30, 253-64	25
504	Neurodegeneration and neuroprotection in Parkinson disease. <b>2004</b> , 1, 139-54	186
503	Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. <b>2004</b> , 318, 225-41	218
502	Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. <b>2004</b> , 318, 215-24	544
501	Redox imbalance. <b>2004</b> , 318, 201-13	160
500	Levodopa in the treatment of Parkinson's disease: current controversies. <b>2004</b> , 19, 997-1005	291
499	Evaluation of animal models of Parkinson's disease for neuroprotective strategies. <b>2004</b> , 139, 121-43	119
498	Preclinical models of Parkinson's disease. <b>2004</b> , Chapter 1, Unit1.8	4
497	Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. <b>2004</b> , 24, 7445-54	86
496	Enzyme Inhibition and Inactivation. <b>2004</b> , 227-321	2
495	My fifty years (almost) of monoamine oxidase. <b>2004</b> , 25, 5-10	3
494	Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?. <b>2004</b> , 25, 279-91	40
493	Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. <b>2004</b> , 15, 561-4	30
492	Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. <b>2005</b> , 1049, 147-55	102
491	Role of peroxidases in Parkinson disease: a hypothesis. <b>2005</b> , 38, 1296-310	40
490	Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging. <b>2005</b> , 207, 251-6	12

489	A microarray study of MPP+-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools. <b>2005</b> , 6 Suppl 2, S8		15
488	Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons. <b>2005</b> , 62, 227-38		23
487	The pedunculopontine tegmental nucleus and experimental parkinsonism. A review. <i>Journal of Neurology</i> , <b>2005</b> , 252 Suppl 4, IV5-IV12	5.5	18
486	Pathophysiology: biochemistry of Parkinson's disease. <b>2005</b> , 598-611		
485	Excitotoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases. <b>2005</b> , 44-56		1
484	Toxic animal models. <b>2005</b> , 196-221		5
483	Toxin-induced models of Parkinson's disease. <b>2005</b> , 2, 484-94		535
482	Parkinson's disease: the first common neurological disease due to auto-intoxication?. <b>2005</b> , 98, 215-26		37
481	Historical neurotoxins: what we have learned from toxins of the past about diseases of the present. <b>2005</b> , 23, 337-52		7
480	Genetics of Parkinson's disease. <b>2005</b> , 37, 86-96		64
479	Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats. <b>2005</b> , 97, 375-81		54
478	A synthetic human proline-rich-polypeptide enhances hydroxyl radical generation and fails to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity in mice. <b>2005</b> , 375, 187-91		7
477	MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. <b>2005</b> , 52, 371-8		25
476	Selective alterations of transcription factors in MPP+-induced neurotoxicity in PC12 cells. <b>2005</b> , 26, 729-37		29
475	Autotoxicity, methylation and a road to the prevention of Parkinson's disease. <b>2005</b> , 12, 6-11		49
474	Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. <b>2005</b> , 65, 353-62		25
473	Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. <b>2005</b> , 163, 159-67		81
472	Nicotinamide: a double edged sword. <b>2005</b> , 11, 413-20		35

471	Temporal evolution of mouse striatal gene expression following MPTP injury. <b>2005</b> , 26, 765-75	16
470	Chapter V Motor function(s) of the nigrostriatal dopamine system: Studies of lesions and behavior. <b>2005</b> , 21, 237-301	6
469	Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline). <b>1994</b> , 738, 214-21	47
468	Intrastratial infusion of the Parkinsonian neurotoxin, MPP(+), induces damage of striatal cell nuclei in Sprague-Dawley rats. <b>2006</b> , 32, 90-100	11
467	Paraquat exposure as an etiological factor of Parkinson's disease. <b>2006</b> , 27, 1110-22	240
466	2,9-Dimethyl-beta-carbolinium, a neurotoxin occurring in human brain, is a potent inducer of apoptosis as 1-methyl-4-phenylpyridinium. <b>2006</b> , 139, 1525-37	22
465	Parkinson Disease. <b>2006</b> ,	1
464	Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-beta-carbolinium ion, a beta-carboline occurring in the human brain. <b>2006</b> , 17, 463-73	16
463	Pedunculopontine nucleus electric stimulation alleviates akinesia independently of dopaminergic mechanisms. <b>2006</b> , 17, 639-41	54
462	The 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. <b>2006</b> , 991, 189-198	222
461	Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. <b>1986</b> , 47, 1073-9	104
460	Central Nervous System Effects of Celastrol, a Potent Antioxidant and Antiinflammatory Agent. <b>2006</b> , 6, 45-62	10
459	LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. <b>2005</b> , 11, 77-96	31
458	Effect of MAO-B inhibitors on MPP+ toxicity in Vivo. <b>2000</b> , 899, 255-61	32
457	Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. <b>2000</b> , 899, 262-73	62
456	Genetics of Parkinson's disease. <b>2000</b> , 920, 28-32	49
455	Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. <b>2006</b> , 53-65	82
454	Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. <b>2006</b> , 26, 781-802	89

453	Synthesis of radiolabelled 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a neurotoxic chloral-derived mammalian alkaloid, and its biodistribution in rats. <b>2006</b> , 28, 412-22		12
452	Basal ganglia lesions after MPTP administration in rhesus monkeys. <i>Neurobiology of Disease</i> , <b>2006</b> , 23, 281-9	7.5	22
451	Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice. <b>2006</b> , 40, 291-8		5
450	The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. <b>2006</b> , 83, 349-59		31
449	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. <b>2006</b> , 21, 1578-94		91
448	An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF neuroprotection. <b>2006</b> , 31, 2708-15		59
447	RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. <b>2006</b> , 26, 9996-10005		135
446	Oxidative Stress and Neuroprotection. <b>2006</b> ,		2
445	Deep-brain stimulation. <b>2007</b> , 2, 633-646		4
444	Salsolinol, a Dopamine-derived Tetrahydroisoquinoline, Occur in Dopaminergic SH-SY5Y Cells Induced by Dopamine. <b>2007</b> ,		
443	Nonhuman primate models of Parkinson's disease. <b>2007</b> , 48, 339-55		124
442	Redox Imbalance: In the Triad of Genetic Disturbances and Mitochondrial Dysfunction in Parkinson's Disease. <b>2007</b> , 183-200		3
441	Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies. <b>2007</b> , 201-218		
440	SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease. <b>2007</b> , 13, 266-75		25
439	Mitochondrial dysfunction in Parkinson's disease. <b>2007</b> , 7, 58-62		81
438	The role of Coenzyme Q in mitochondrial electron transport. <b>2007</b> , 7 Suppl, S8-33		141
437	Parkinson's Disease. <b>2007</b> ,		1
436	Transplantation. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2007</b> , 84, 279-90	3	1

435	Mitochondria in the etiology of Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 479-91</i>	3	7
434	Toxic causes of parkinsonism. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 385-98</i>	3	
433	History of Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 107-28</i>	3	6
432	Dopamine receptor pharmacology. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 77-105</i>	3	10
431	Experimental Models and New, Emerging Therapies for Parkinson Disease. <b>2007, 205-231</b>		
430	Exogenous Acquired Metabolic Disorders of the Nervous System. <b>2007, 865-896</b>		4
429	Medical Treatment of Parkinson Disease. <b>2007, 129-165</b>		2
428	Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>2007, 22, 99-104</b>		28
427	Cytotoxicity of beta-carbolines in dopamine transporter expressing cells: structure-activity relationships. <b>2007, 74, 1065-77</b>		23
426	Toxic influence of subchronic paraquat administration on dopaminergic neurons in rats. <b>2007, 1155, 196-207</b>		60
425	Apoptotic mode of cell death in substantia nigra following intranigral infusion of the parkinsonian neurotoxin, MPP+ in Sprague-Dawley rats: cellular, molecular and ultrastructural evidences. <b>2007, 32, 1238-47</b>		13
424	Increased dopaminergic neuron sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in transgenic mice expressing mutant A53T alpha-synuclein. <b>2008, 33, 902-11</b>		33
423	Calpain-mediated MPP+ toxicity in mitochondrial DNA depleted cells. <b>2008, 13, 31-8</b>		11
422	Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: relationship with low levels of regional monoamine oxidase B. <b>1994, 62, 1906-12</b>		39
421	Physiology of MPTP tremor. <b>1998, 13 Suppl 3, 29-34</b>		60
420	Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B. <b>2008, 16, 8813-7</b>		3
419	Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease. <b>2008, 3, 447-461</b>		1
418	Methamphetamine fails to alter the noradrenergic integrity of the heart. <b>2008, 1139, 337-44</b>		9

417	Emerging pathways in genetic Parkinson's disease: autosomal-recessive genes in Parkinson's disease--a common pathway?. <b>2008</b> , 275, 5758-66	52
416	Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. <b>2008</b> , 104, 1309-20	21
415	Mitochondrial DNA, base excision repair and neurodegeneration. <b>2008</b> , 7, 1098-109	73
414	Advances in Alzheimer's and Parkinson's Disease. <b>2008</b> ,	
413	9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. <b>2008</b> , 52, 688-700	31
412	Role of CYP2E1 in the mouse model of MPTP toxicity. <b>2008</b> , 14 Suppl 2, S119-23	9
411	Progress in Parkinson's disease-where do we stand?. <b>2008</b> , 85, 376-92	140
410	The role of MPTP in Parkinson's disease: connecting brain and gut?. <b>2008</b> , 210, 281-5	6
409	Development of a stable, early stage unilateral model of Parkinson's disease in middle-aged rhesus monkeys. <b>2008</b> , 212, 431-9	21
408	A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs. <b>2008</b> , 194, 152-61	24
407	Contributions of non-human primates to neuroscience research. <b>2008</b> , 371, 1126-35	158
406	Progress in the pathogenesis and genetics of Parkinson's disease. <b>2008</b> , 363, 2215-27	59
405	Can we prevent parkinson's disease?. <b>2009</b> , 14, 1642-60	4
404	The Role of Drug Metabolism in Toxicity. 559-628	1
403	Four decades of neurodegenerative disease research: how far we have come!. <b>2009</b> , 29, 12722-8	45
402	Cell-based therapies for Parkinson's disease: past, present, and future. <b>2009</b> , 11, 2189-208	24
401	Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. <i>Neurobiology of Disease</i> , <b>2009</b> , 36, 303-11	7.5 38
400	Accumulation of a parkinsonism-inducing neurotoxin in melanin-bearing neurons: autoradiographic studies on 3H-MPTP. <b>1986</b> , 59, 161-4	12

399	Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. <b>2008</b> , 64 Suppl 2, S16-29		62
398	Alterations of nocturnal activity in rats following subchronic oral administration of the neurotoxin 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline. <b>2009</b> , 116, 1267-71		5
397	Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. <b>2009</b> , 39, 149-70		136
396	The application of Russell and Burch 3R principle in rodent models of neurodegenerative disease: the case of Parkinson's disease. <b>2009</b> , 33, 18-32		36
395	Neurodegeneration and peroxidases. <b>2009</b> , 30, 1011-25		36
394	MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice. <b>2009</b> , 56, 1075-81		14
393	Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. <b>2009</b> , 55, 760-7		39
392	Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO). <b>2009</b> , 43, 975-84		14
391	Chapter 33: the history of movement disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2010</b> , 95, 501-46	3	48
390	Oxidative Neural Injury. <b>2009</b> ,		
389	Methamphetamine-induced neurotoxicity: the road to Parkinson's disease. <b>2009</b> , 61, 966-77		59
388	Syntheses and Uses of Isotopically Labelled Organic Halides. <b>2009</b> ,		
387	Protocatechuic acid inhibits rat pheochromocytoma cell damage induced by a dopaminergic neurotoxin. <b>2009</b> , 32, 1866-9		23
386	Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. <b>2010</b> , 3, 194-208		147
385	α-Synuclein: membrane interactions and toxicity in Parkinson's disease. <b>2010</b> , 26, 211-33		399
384	Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. <b>2010</b> , 49, 1674-84		132
383	Parkinson's Disease. <b>2010</b> , 593-606		
382	[Parkinson's disease: Role of genetic and environment factors. Involvement in everyday clinical practice]. <b>2010</b> , 166, 764-9		7



381	Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. <b>2010</b> , 474, 99-103	43
380	Mitochondrial dysfunction in Parkinson's disease. <b>2010</b> , 1802, 29-44	383
379	Microdialysis study of striatal dopamine in MPTP-hemilesioned rats challenged with apomorphine and amphetamine. <b>2010</b> , 215, 63-70	7
378	Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. <b>2010</b> , 169, 1085-93	14
377	Therapeutic and Diagnostic Agents for Parkinson's Disease. <b>2010</b> , 529-568	
376	Towards model-based control of Parkinson's disease. <b>2010</b> , 368, 2269-308	84
375	Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain. <b>2011</b> , 21, 171-82	11
374	Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease. <b>2011</b> , 3, 21	14
373	Using the MPTP Mouse Model to Understand Neuroplasticity: A New Therapeutic Target for Parkinson's Disease?. <b>2011</b> , 353-369	
372	Basal Ganglia. <b>2011</b> , 495-564	2
371	Biochemical and toxicological evidence of neurological effects of pesticides: the example of Parkinson's disease. <b>2011</b> , 32, 383-91	90
370	Computational physiology of the neural networks of the primate globus pallidus: function and dysfunction. <b>2011</b> , 198, 171-92	31
369	Protection by tetrahydroxystilbene glucoside against neurotoxicity induced by MPP+: the involvement of PI3K/Akt pathway activation. <i>Toxicology Letters</i> , <b>2011</b> , 202, 1-7	4.4 68
368	Genetic mutations and mitochondrial toxins shed new light on the pathogenesis of Parkinson's disease. <b>2011</b> , 2011, 979231	8
367	Toxin-induced and genetic animal models of Parkinson's disease. <b>2010</b> , 2011, 951709	42
366	Mitochondrial dysfunction in Parkinson's disease. <b>2011</b> , 2011, 716871	78
365	Knowing me, knowing you: can a knowledge of risk factors for Alzheimer's disease prove useful in understanding the pathogenesis of Parkinson's disease?. <b>2011</b> , 25, 395-415	22
364	Systematic review of parkinsonian syndromes in short- and long-term survivors of paraquat poisoning. <b>2011</b> , 53, 1332-6	16

363	Amphetamine-induced circling behaviour in MPTP-lesioned mice. <b>1985</b> , 37, 922-3	1
362	The effects of 1-methyl-4-phenylpyridinium ion (MPP+) on the efflux and metabolism of endogenous dopamine in rat striatal slices. <b>1988</b> , 40, 620-6	10
361	Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on dopamine metabolism in mouse and rat striatum. <b>1985</b> , 37, 707-11	40
360	MPTP mouse models of Parkinson's disease: an update. <b>2011</b> , 1, 19-33	235
359	The histopathology of drugs of abuse. <b>2011</b> , 59, 579-93	48
358	Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. <b>2011</b> , 164, 1357-91	443
357	Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, <i>Streptomyces</i> sp. <b>2011</b> , 21, 5715-8	26
356	Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases. <b>2011</b> , 255-288	16
355	The MPTP-Treated Primate, with Specific Reference to the Use of the Common Marmoset ( <i>Callithrix jacchus</i> ). <b>2011</b> , 371-400	3
354	Basic science in Parkinson's disease: its impact on clinical practice. <i>Journal of Neurology</i> , <b>2011</b> , 258, S299-306	4
353	Parkinson's disease mouse models in translational research. <b>2011</b> , 22, 401-19	52
352	Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials. <b>2011</b> , 8, 549-61	42
351	The most cited works in Parkinson's disease. <b>2011</b> , 26, 380-90	43
350	Milestones in research on the pathophysiology of Parkinson's disease. <b>2011</b> , 26, 1032-41	143
349	A guide to neurotoxic animal models of Parkinson's disease. <b>2011</b> , 1, a009316	297
348	Medical treatment of Parkinson disease. <b>2011</b> , 119-156	
347	Mitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 8722-39	6.3 46
346	The Use of Stem Cells in Regenerative Medicine for Parkinson's and Huntington's Diseases. <b>2012</b> , 19, 6018-6035	7

345	1-Methyl-4-phenyl-1,2,5,6-Tetrahydropyridine (MPTP). <b>2012</b> , 603-607	
344	Recent updates in redox regulation and free radical scavenging effects by herbal products in experimental models of Parkinson's disease. <b>2012</b> , 17, 11391-420	24
343	Neurotoxin-based models of Parkinson's disease. <b>2012</b> , 211, 51-76	342
342	Can Parkinson's disease pathology be propagated from one neuron to another?. <b>2012</b> , 97, 205-19	83
341	Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. <b>2012</b> , 31, 3038-62	388
340	Mitochondria: in sickness and in health. <b>2012</b> , 148, 1145-59	1702
339	Parkinson's disease. <b>2012</b> , 65, 389-455	184
338	Systems Biology of Parkinson's Disease. <b>2012</b> ,	6
337	▯ nicotinic acetylcholine receptor mediated neuroprotection in Parkinson's disease. <b>2012</b> , 13, 623-30	35
336	Animal Models of Movement Disorders. <b>2012</b> ,	
335	Animal Models of Parkinson's Disease Induced by Toxins and Genetic Manipulation. <b>2012</b> ,	
334	Cooperative action of JNK and AKT/mTOR in 1-methyl-4-phenylpyridinium-induced autophagy of neuronal PC12 cells. <b>2012</b> , 90, 1850-60	29
333	Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. <b>2012</b> , 119, 435-41	30
332	Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. <b>2012</b> , 33, 169-78	47
331	Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. <b>2012</b> , 123, 173-88	103
330	Complexity of dopamine metabolism. <b>2013</b> , 11, 34	321
329	Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders. <b>2013</b> , 714, 486-97	30
328	SUMO and Parkinson's disease. <b>2013</b> , 15, 737-59	36

327	Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. <b>2013</b> , 5, 91-109	51
326	Handbook of Parkinson's Disease. <b>2013</b> ,	11
325	Mitochondrial dysfunction and oxidative stress in Parkinson's disease. <b>2013</b> , 106-107, 17-32	369
324	Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NM-salsolinol. <b>2013</b> , 233, 72-85	20
323	Cognitive deficits in animal models of basal ganglia disorders. <b>2013</b> , 92, 29-40	9
322	Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B. <b>2013</b> , 65, 127-33	5
321	APP+, a fluorescent analogue of the neurotoxin MPP+, is a marker of catecholamine neurons in brain tissue, but not a fluorescent false neurotransmitter. <b>2013</b> , 4, 858-69	22
320	Determination of Endogenous Neurotoxin 1-Acetyl-6,7-Dihydroxyl-1,2,3,4-Tetrahydroisoquinoline in Rat Substantia Nigra by High Performance Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry. <b>2013</b> , 46, 2828-2834	1
319	An alternative medical approach for the neuroprotective therapy to slow the progression of Parkinson's disease. <b>2013</b> , 133, 849-56	3
318	Neuropathology of parkinsonism. <b>2013</b> , 253-271	
317	Pluripotent stem cell-derived dopaminergic neurons as models of neurodegeneration. <b>2013</b> , 8, 649-661	0
316	The role of innate and adaptive immunity in Parkinson's disease. <b>2013</b> , 3, 493-514	181
315	Autophagy: A Possible Defense Mechanism in Parkinson's Disease?. <b>2013</b> ,	
314	Fetal and Environmental Basis for the Cause of Parkinson's Disease. <b>2013</b> ,	
313	Identification of licopyranocoumarin and glycyrurol from herbal medicines as neuroprotective compounds for Parkinson's disease. <b>2014</b> , 9, e100395	15
312	miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. <b>2014</b> , 8, 182	91
311	The origins of psychopharma. 1-12	
310	Some preliminaries. 13-34	

309	Nonhuman primate models in translational regenerative medicine. <b>2014</b> , 23 Suppl 1, 83-7	14
308	The perplexing paradox of paraquat: the case for host-based susceptibility and postulated neurodegenerative effects. <b>2014</b> , 28, 191-7	16
307	Enzyme Inhibition and Inactivation. <b>2014</b> , 207-274	1
306	Glutamate as a Neurotoxin. <b>2014</b> , 365-397	1
305	Integrating pathways of Parkinson's disease in a molecular interaction map. <b>2014</b> , 49, 88-102	178
304	Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs. <b>2014</b> , 31, 880-904	45
303	α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease. <b>2014</b> , 67, 58-68	24
302	Methylglyoxal increases dopamine level and leads to oxidative stress in SH-SY5Y cells. <b>2014</b> , 46, 950-6	12
301	Neuroinflammation in Parkinson's disease animal models: a cell stress response or a step in neurodegeneration?. <b>2015</b> , 22, 237-70	43
300	Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease. <b>2014</b> , 119, 87-116	21
299	Modeling dyskinesia in animal models of Parkinson disease. <b>2014</b> , 256, 105-16	66
298	Progressive loss of striatal dopamine terminals in MPTP-induced acute parkinsonism in cynomolgus monkeys using vesicular monoamine transporter type 2 PET imaging ([ <sup>18</sup> F]AV-133). <b>2014</b> , 30, 409-16	8
297	Inflammation in Parkinson's Disease. <b>2014</b> ,	3
296	Levodopa-Induced Dyskinesia in Parkinson's Disease. <b>2014</b> ,	2
295	The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. <b>2014</b> , 10, S213-25	55
294	Stimulation of electron transport as potential novel therapy in Parkinson's disease with mitochondrial dysfunction. <b>2015</b> , 43, 275-9	9
293	Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease. <b>2015</b> , 78, 1000-4	67
292	Modeling Parkinson's disease in the common marmoset ( <i>Callithrix jacchus</i> ): overview of models, methods, and animal care. <b>2015</b> , 31, 155-65	38

291	Extrapyramidal system neurotoxicity: animal models. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2015</b> , 131, 207-23	3	4
290	Systems biology analysis of the proteomic alterations induced by MPP(+), a Parkinson's disease-related mitochondrial toxin. <b>2015</b> , 9, 14		20
289	Motor Pathways, Basal Ganglia Physiology, and Pathophysiology. <b>2015</b> , 29-44		2
288	Behavioral Neurobiology of Huntington's Disease and Parkinson's Disease. <b>2015</b> ,		12
287	Rodent Models of Autosomal Dominant Parkinson Disease. <b>2015</b> , 307-328		
286	The Docosanoid Neuroprotectin D1 Induces TH-Positive Neuronal Survival in a Cellular Model of Parkinson's Disease. <b>2015</b> , 35, 1127-36		11
285	Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure. <b>2015</b> , 290, 6799-809		35
284	Salsolinol Damaged Neuroblastoma SH-SY5Y Cells Induce Proliferation of Human Monocyte THP-1 Cells Through the mTOR Pathway in a Co-culture System. <b>2015</b> , 40, 932-41		2
283	Transplantation of human mesenchymal stem cells into the cisterna magna and its neuroprotective effects in a parkinsonian animal model. <b>2015</b> , 11, 373-385		6
282	The impact of combined administration of paraquat and maneb on motor and non-motor functions in the rat. <b>2015</b> , 311, 118-29		22
281	Manganese-Induced Parkinsonism Is Not Idiopathic Parkinson's Disease: Environmental and Genetic Evidence. <b>2015</b> , 146, 204-12		66
280	αSynuclein and nonhuman primate models of Parkinson's disease. <b>2015</b> , 255, 38-51		23
279	[Is Parkinson's disease a prion disease?]. <b>2015</b> , 171, 812-24		5
278	Therapeutic strategies in Parkinson's disease: what we have learned from animal models. <b>2015</b> , 1338, 16-37		24
277	Neurotoxicology. <b>2016</b> ,		
276	Oxidative Stress and Parkinson's Disease: Effects on Environmental Toxicology. <b>2016</b> ,		2
275	Etiology and Progression of Parkinson's Disease: Cross-Talk Between Environmental Factors and Genetic Vulnerability. <b>2016</b> , 24, 803-819		1
274	Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. <b>2016</b> , 13, 100-109		3

273	Induced pluripotent stem cells and Parkinson's disease: modelling and treatment. <b>2016</b> , 49, 14-26	11
272	New insights on the mitochondrial proteome plasticity in Parkinson's disease. <b>2016</b> , 10, 416-29	8
271	Deep brain stimulation for Parkinson's disease: current status and future outlook. <b>2016</b> , 6, 299-317	3
270	Organic Cation Transporters as Modulators of Neurodegeneration and Neuroprotection in the Brain. <b>2016</b> , 205-216	
269	Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. <b>2016</b> , 38, 216.e7-216.e10	131
268	Organic Cation Transporters. <b>2016</b> ,	1
267	Parkinson's Disease. <b>2017</b> , 477-492	
266	Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease. <b>2017</b> , 32, 346-363	92
265	The emerging role of retromer in neuroprotection. <b>2017</b> , 47, 72-82	43
264	Cannabinoid Therapeutics in Parkinson's Disease: Promise and Paradox. <b>2017</b> , 23, 231-248	7
263	Etiology and Pathogenesis of Parkinson Disease. <b>2017</b> , 46-52	1
262	MicroRNAs in Parkinson's disease. <b>2017</b> , 235, 2359-2374	51
261	The two-century journey of Parkinson disease research. <b>2017</b> , 18, 251-259	186
260	Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models. <b>2017</b> , 19, 241-255	13
259	ATP Maintenance via Two Types of ATP Regulators Mitigates Pathological Phenotypes in Mouse Models of Parkinson's Disease. <b>2017</b> , 22, 225-241	30
258	Nonclinical Safety Assessment of Cell-Based Therapies. <b>2017</b> , 647-657	
257	Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease. <b>2017</b> , 82, 1016-1021	32
256	6-Hydroxydopamine induces nuclear translocation of apoptosis inducing factor in nigral dopaminergic neurons in rat. <b>2017</b> , 13, 305-315	2

255	The Synucleinopathies: Twenty Years On. <b>2017</b> , 7, S51-S69		200
254	Current Status, Gaps, and Weaknesses of the Mechanism of Selective Dopaminergic Toxicity of MPTP/MPP+. <b>2017</b> , 11, 81-122		4
253	. <b>2017</b> ,		1
252	Loss of PINK1 or Parkin Function Results in a Progressive Loss of Mitochondrial Function. <b>2017</b> , 187-209		1
251	The MPTP Story. <b>2017</b> , 7, S11-S19		194
250	ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	51
249	Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease. <b>2017</b> , 9, 176		162
248	Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's Disease. <b>2017</b> , 2017, 9349487		30
247	Electron Transport Chain. <b>2017</b> , 41-75		0
246	Dietary Phytochemicals in Neurodegenerative Disease. <b>2017</b> , 361-391		4
245	Nicotinic Acetylcholine Receptor Signaling in Neuroprotection. <b>2018</b> ,		4
244	Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. <b>2018</b> , 125, 1735-1749		52
243	Trichloroethylene and Parkinson's Disease: Risk Assessment. <b>2018</b> , 55, 6201-6214		17
242	Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH-MPTP: A Novel Approach. <b>2018</b> , 20, 73-82		1
241	Baseline striatal and nigral interneuronal protein levels in two distinct mice strains differ in accordance with their MPTP susceptibility. <b>2018</b> , 91, 46-54		4
240	Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey. <b>2018</b> , 365, 379-397		23
239	Non-human primate models of PD to test novel therapies. <b>2018</b> , 125, 291-324		26
238	α-Synuclein nonhuman primate models of Parkinson's disease. <b>2018</b> , 125, 385-400		18



237	The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease. <b>2018</b> , 125, 365-384	7
236	Basal ganglia, movement disorders and deep brain stimulation: advances made through non-human primate research. <b>2018</b> , 125, 419-430	35
235	Advances in Parkinson's Disease: 200 Years Later. <b>2018</b> , 12, 113	65
234	Reprint of "Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms". <b>2018</b> , 310, 75-88	3
233	Histologic Changes In Recreational Drug Misuse. <b>2018</b> , 8, 653-691	2
232	Cellular Models: HD Patient-Derived Pluripotent Stem Cells. <b>2018</b> , 1780, 41-73	6
231	Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer's and Parkinson's Diseases. <b>2018</b> , 137-158	10
230	Ferritin and neuromelanin "quantum dot" array structures in dopamine neurons of the substantia nigra pars compacta and norepinephrine neurons of the locus coeruleus. <b>2018</b> , 171, 48-58	7
229	Loss of Parkin impairs mitochondrial function and leads to muscle atrophy. <b>2018</b> , 315, C164-C185	30
228	Nrf2 activation attenuates the early suppression of mitochondrial respiration due to the $\alpha$ -Synuclein overexpression. <b>2018</b> , 41, 169-183	18
227	Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases and : Regulation of Redox Biology and Mitochondrial Function. <b>2018</b> , 10, 121	34
226	An investigation into closed-loop treatment of neurological disorders based on sensing mitochondrial dysfunction. <b>2018</b> , 15, 8	8
225	Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms. <b>2018</b> , 308, 205-218	19
224	Parkinson's Disease in Humans and in Nonhuman Primate Aging and Neurotoxin Models. <b>2018</b> , 617-639	1
223	Human tyrosine hydroxylase in Parkinson's disease and in related disorders. <b>2019</b> , 126, 397-409	42
222	Neuroprotective Effect of Schisandra Chinensis on Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonian Syndrome in C57BL/6 Mice. <b>2019</b> , 11,	7
221	The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3 42
220	Current Progress of Mitochondrial Quality Control Pathways Underlying the Pathogenesis of Parkinson's Disease. <b>2019</b> , 2019, 4578462	19

219	ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson's disease. <b>2019</b> , 51, 1-13		19
218	WITHDRAWN: Forty years of Editorship of Psychiatry Research. <i>Psychiatry Research</i> , <b>2019</b> ,	9.9	
217	Potential Role of Mic60/Mitofilin in Parkinson's Disease. <b>2018</b> , 12, 898		7
216	Introduction and classical environmental risk factors for Parkinson. <b>2019</b> , 175, 650-651		3
215	The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects. <b>2019</b> , 129, 104495		12
214	A secret that underlies Parkinson's disease: The damaging cycle. <b>2019</b> , 129, 104484		11
213	Dietary Macronutrient Management to Treat Mitochondrial Dysfunction in Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	11
212	Forty years of editorship of psychiatry research. <i>Psychiatry Research</i> , <b>2019</b> , 277, 4-9	9.9	0
211	Classic animal models of Parkinson's disease: a historical perspective. <b>2019</b> , 30, 291-310		14
210	Autoimmunity in Parkinson's Disease: The Role of $\alpha$ -Synuclein-Specific T Cells. <b>2019</b> , 10, 303		76
209	$\alpha$ -Synuclein Expression Is Preserved in Substantia Nigra GABAergic Fibers of Young and Aged Neurotoxin-Treated Rhesus Monkeys. <b>2019</b> , 28, 379-387		3
208	Plant poisoning leads to alpha-synucleinopathy and neuromelanopathy in kangaroos. <b>2019</b> , 9, 16546		1
207	Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. <b>2019</b> , 12, 299		91
206	New insights into the complex role of mitochondria in Parkinson's disease. <b>2019</b> , 177, 73-93		138
205	The hidden side of Parkinson's disease: Studying pain, anxiety and depression in animal models. <b>2019</b> , 96, 335-352		29
204	Neurotheranostics as personalized medicines. <b>2019</b> , 148, 252-289		36
203	Parkinson's Disease. <b>2019</b> , 83-121		2
202	Celastrol Inhibits Dopaminergic Neuronal Death of Parkinson's Disease through Activating Mitophagy. <b>2019</b> , 9,		25

201	Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson's Disease. <b>2020</b> , 9,	12
200	Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes. <b>2020</b> , 14, 567129	15
199	Parkinson's disease. <b>2020</b> , 377-412	2
198	Animal models of central nervous system disorders. <b>2020</b> , 621-650	
197	Xanthotoxin reverses Parkinson's disease-like symptoms in zebrafish larvae and mice models: a comparative study. <b>2021</b> , 73, 122-129	4
196	Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more <b>2021</b> , 177, 260-271	6
195	Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects. <b>2021</b> , 11, 45-60	21
194	Addicts $\square$ Neurotoxins that cause parkinsonism and the search for analogues in the environment. <b>2021</b> , 113-128	
193	Mitochondrial abnormalities in neurological disorders. <b>2021</b> , 193-245	
192	Medical treatment of the motor features of Parkinson disease. <b>2021</b> , 164-203.e14	1
191	Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk. <b>2021</b> , 36, 815-831	3
190	Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson's disease. <b>2021</b> , 12, 181	6
189	Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks. <b>2021</b> , 39, 897-923	7
188	Interpreting the role of the striatum during multiple phases of motor learning. <b>2021</b> ,	5
187	Contribution of the Nrf2 Pathway on Oxidative Damage and Mitochondrial Failure in Parkinson and Alzheimer's Disease. <b>2021</b> , 10,	13
186	Antioxidant Effect of Hydroxytyrosol, Hydroxytyrosol Acetate and Nitrohydroxytyrosol in a Rat MPP Model of Parkinson's Disease. <b>2021</b> , 46, 2923-2935	3
185	Cell-Type-Specific High Throughput Toxicity Testing in Human Midbrain Organoids. <b>2021</b> , 14, 715054	5
184	Epidermal Fatty Acid-Binding Protein 5 (FABP5) Involvement in Alpha-Synuclein-Induced Mitochondrial Injury under Oxidative Stress. <b>2021</b> , 9,	5

183	The significance of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <b>1987</b> , 126, 239-56	3
182	Parkinson's Disease. <b>2007</b> , 1-19	2
181	Biomarkers for Early Detection of Parkinson's Disease: An Essential Challenge. <b>2008</b> , 35-49	2
180	Neural Network Modeling of Voluntary Single-Joint Movement Organization II. Parkinson's Disease. <b>2010</b> , 193-212	5
179	Dopamine Neurone Destruction in Human and Animal Parkinsonism. <b>1986</b> , 243-259	1
178	Fetal Substantia Nigra Transplants Lead to Dopamine Cell Replacement and Behavioral Improvement in Bonnet Monkeys with MPTP Induced Parkinsonism. <b>1988</b> , 353-360	15
177	Pyridine derivatives: structure-activity relationships causing parkinsonism-like symptoms. <b>1991</b> , 122, 1-36	6
176	Dopaminergic Neurons in the Substantia Nigra in Normal Aging and MPTP-Lesioned Mice. <b>1990</b> , 497-500	1
175	The Current Clinical Picture Of Parkinson's Disease. <b>1988</b> , 1-10	2
174	Search For Environmental Or Endogenous Neurotoxins Related To MPTP. <b>1988</b> , 85-91	1
173	Studies on the Toxicity of MPTP to Dopamine Neurons in Tissue and Cell Cultures. <b>1988</b> , 127-136	3
172	Possible Dopaminergic Basis for Perceptual Motor Dysfunction. <b>1986</b> , 185-189	4
171	MPTP-Induced Parkinsonian Syndromes in Humans and Animals. <b>1986</b> , 519-530	8
170	Mathematical Models of Dopamine Metabolism in Parkinson's Disease. <b>2012</b> , 151-171	2
169	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. <b>2014</b> , 237-275	2
168	Advances in our Knowledge of MPTP Action and Mechanism. <b>2000</b> , 41-53	1
167	Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications. <b>1995</b> , 363, 17-23	8
166	Behavioral and Neuropathological Consequences of Chronic Exposure to Low Doses of the Dopaminergic Neurotoxin MPTP. <b>1992</b> , 293-308	5

165	Molecular Approaches to Human Neurological Diseases and Their Animal Models. <b>1986</b> , 171-180	1
164	Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson's Disease. <b>1986</b> , 53-81	6
163	The tuberoinfundibular dopaminergic neurons of the brain: hormonal regulation. <b>1990</b> , 274, 1-23	5
162	Endogenous MPTP-Like Amines in the Brain: Isoquinolines. <b>1994</b> , 149-159	1
161	Push-Pull Model of Dopamine's Action in the Retina. <b>2002</b> , 191-214	4
160	MPTP-Treated Mice: A Useful Model for Parkinson's Disease?. <b>1994</b> , 121-137	3
159	Behavioral Effects of MPTP Administration in the Vervet Monkey. <b>1994</b> , 139-174	21
158	The Use of Neurotoxins to Lesion Catecholamine-Containing Neurons to Model Clinical Disorders. <b>1998</b> , 19-73	11
157	MPTP. <b>1998</b> , 141-194	14
156	Haloperidol-Derived Pyridinium Metabolites. <b>1998</b> , 195-210	3
155	Neuroprotective Strategies in Parkinson's Disease and Huntington's Chorea. <b>2000</b> , 293-309	1
154	Behavioral Assessment in the African Green Monkey After MPTP Administration. <b>2011</b> , 401-435	5
153	MAO-B Inhibitors in Neurological Disorders with Special Reference to Selegiline. <b>1993</b> , 253-275	3
152	The Therapeutic Place and Value of Present and Future MAO-B Inhibitors – Deprenyl as the Gold Standard. <b>1993</b> , 327-338	5
151	Neurotoxins and Monoamine Oxidase B Inhibitors: Possible Mechanisms for the Neuroprotective Effect of (R)-Deprenyl. <b>1993</b> , 169-181	6
150	The Effect of Chronic Nicotine Treatment on 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Degeneration of Nigrostriatal Dopamine Neurons in the Black Mouse. <b>1991</b> , 323-329	3
149	The relationship of early studies of monoamine oxidase to present concepts. <b>2006</b> , 79-86	4
148	Neurophysiology of Basal Ganglia. <b>1989</b> , 1-45	2

147	Pathology of Parkinson's Syndrome. <b>1989</b> , 47-112	23
146	Transplantation of Fetal Dopamine-Synthesizing Cells: Experiment or Therapy of Parkinson's Disease?. <b>1991</b> , 467-483	1
145	Spezielle Syntheseverfahren mit kurzlebigen Radionukliden und Qualitätskontrolle. <b>1988</b> , 31-117	2
144	Mechanisms of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Induced Destruction of Dopaminergic Neurons. <b>1994</b> , 333-356	1
143	Molecular and Cellular Events Regulating Dopamine Neuron Survival. <b>2002</b> , 321-386	4
142	Toxin Induced Mitochondrial Dysfunction and Neurodegeneration. <b>1998</b> , 297-317	4
141	Dopaminforschung heute und morgen [L-Dopa in der Zukunft. <b>1985</b> , 127-144	22
140	The MPTP model: an update. <b>1989</b> , 237-242	1
139	Histochemistry of MAO subtypes in the brainstem of humans: a relation to the radical hypothesis of Parkinson's disease?. <b>1989</b> , 243-248	7
138	Senile dementia of Alzheimer's type and Parkinson's disease: neurochemical overlaps and specific differences. <b>1990</b> , 221-232	6
137	Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP. <b>1994</b> , 41, 207-19	5
136	Dopamine Reuptake Sites: The Issues. <b>1991</b> , 111-119	1
135	Mitochondrial Proteins in the Development of Parkinson's Disease. <b>2019</b> , 1158, 17-44	2
134	Neurodegeneration and neuroprotection in Parkinson disease. <b>2004</b> , 1, 139	1
133	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. <b>2020</b> , 57, 2959-2980	60
132	Enzyme Inhibition and Inactivation. <b>1992</b> , 146-219	2
131	Lesioning of Rat Nigrostriatal Dopamine Pathway with 1-Methyl-4-phenylpyridinium Ion (MPP+). <b>1991</b> , 7, 3-15	2
130	The Neuropathology of Movement Disorders in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone (Ephedrone) Addictions. <b>2016</b> , 924-934	2

129	MPTP and neurotoxins induced neuronal cell death. <b>1993</b> , 105-122	2
128	Disruption of Energy Metabolism and Mitochondrial Function. <b>1995</b> , 483-490	2
127	Restorative Surgical Therapies for Parkinson's Disease. <b>1999</b> , 389-X	2
126	Nervous System and Special Sense Organs. <b>2000</b> , 823-883	1
125	β-Endorphin. <b>2011</b> , 1-8	0
124	Les opioïdes. <b>2007</b> , 53-127	1
123	Deuterium Isotope Effect Measurements on the Interactions of the Neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with Monoamine Oxidase B. <b>1989</b> , 264, 13684-13688	34
122	Opioids and Designer Drugs. <b>1990</b> , 8, 495-511	14
121	Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys. <b>1995</b> , 37, 733-741	8
120	Relationship between Microglial Activation and Dopaminergic Neuronal Loss in 6-OHDA-induced Parkinsonian Animal Model. <b>2013</b> , 26, 13	1
119	Long-term effects of cogafts of pretransected peripheral nerve with adrenal medulla in animal models of Parkinson's disease. <b>1993</b> , 33, 685-90	10
118	Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. <b>2016</b> , 11, e0151020	29
117	Targeted deletion of the aquaglyceroporin AQP9 is protective in a mouse model of Parkinson's disease. <b>2018</b> , 13, e0194896	10
116	1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): One Designer Drug and Serendipity. <b>1988</b> , 33, 11978J	15
115	The Characterization of Some 3,4-Methylenedioxyphenylisopropylamine (MDA) Analogs. <b>1989</b> , 34, 12722J	18
114	β-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin. <b>2017</b> , 4,	40
113	Neuroprotective Strategies for Neurological Disorders by Natural Products: An update. <b>2019</b> , 17, 247-267	64
112	[Nitric oxide, neurodegeneration, and Parkinson's disease]. <b>2005</b> , 62, 751-6	3

- 111 Chemically Induced Models of Parkinson's Disease: History and Perspectives for the Involvement of Ferroptosis. **2020**, 14, 581191 6
- 110 Nonhuman primate model in clinical modeling of diseases for stem cell therapy. **2016**, 2, 141-145 1
- 109 Mitochondrial DNA--related mitochondrial dysfunction in neurodegenerative diseases. **2002**, 126, 271-80 37
- 108 Neuroprotective effects of Sohaphwangwon essential oil in a Parkinson's disease mouse model. **2012**, 23, 129-143 2
- 107 MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. **2021**, 1-41
- 106 Case Report: Synucleinopathy Associated With Neurotoxicity in Sheep. **2021**, 8, 736567 0
- 105 Isoquinoline Neurotoxins. **2000**, 69-76
- 104 Therapeutic and Diagnostic Agents for Parkinson's Disease. **2003**, 711-741 8
- 103 Die Parkinson-Krankheit. **2004**, 200-227
- 102 Pathophysiologie der Basalganglien. **2004**, 57-81
- 101 Xenobiotic Metabolism and Idiopathic Parkinson's Disease. **2004**, 188-206
- 100 Pathology of Drug Abuse. **2006**, 71-145
- 99 Functional Neuroanatomy of the Basal Ganglia. **2007**, 65-77
- 98 Environmental and Genetic Interactions: Key to Sporadic Parkinson's Disease?. **2007**, 607-619
- 97 Disorders of the Central Nervous System. **2007**, 137-151
- 96 Opiates and Opioids. **2008**, 367-374
- 95 Molecular, Cellular and Electrophysiological Changes Triggered by High-Frequency Stimulation of the Subthalamic Nucleus in Animal Models of Parkinson's Disease. **2009**, 1-36
- 94 Protein Oxidation Triggers the Unfolded Protein Response and Neuronal Injury in Chemically Induced Parkinson Disease. **2009**, 179-192



- 93 Effects of dopamine depletion on reward-seeking behavior. **2009**, 271-289
- 92 Parkinson's Disease. **2009**, 917-922
- 91 Abnormal Movements and Difficulty Walking Due to Central Nervous System Problems. **2010**, 281-304
- 90 The Role of Drug Metabolism in Toxicity. 1
- 89 Combination Lesion Models of MSA. **2011**, 37-54
- 88 Impact of Aging on Brain Structure and Function in Rodents and Canines. 125-138
- 87 Animal models of Parkinson's disease and related disorders. **2013**, 281-316
- 86 Differential diagnosis. **2013**, 40-60 1
- 85 Animal Models for PD and ALS. **2014**, 497-526
- 84 Role of the Innate and Adaptive Immune System in the Pathogenesis of PD. **2014**, 75-103 1
- 83 Preclinical Models of Levodopa-Induced Dyskinesia. **2014**, 335-353
- 82 2?-NH<sub>2</sub>-MPTP: A Serotonin and Norepinephrine Neurotoxin. **2014**, 327-346
- 81 Entwicklung dopaminergischer Mittel für die Behandlung der Parkinson-Krankheit und anderer neurogeriatrischer Erkrankungen: Experimental-Modelle. **1985**, 13-27
- 80 Monoamine Oxidase Type B Inhibitors in Human and Animal Parkinsonism. **1986**, 655-668
- 79 Tissue Culture in Studies of Aging in the Nervous System: Toxicity of MPTP to Dopamine Neurons. **1987**, 491-500 1
- 78 Parkinsonian Syndrome Caused by 1-Methyl-4-Phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Man and Animals. **1987**, 213-248 0
- 77 Behavioral Performance Improves After Fetal Substantia Nigra Transplant in Bonnet Monkeys with MPTP Induced Parkinsonism. **1988**, 193-196
- 76 Recent Advances In Dopaminergic Implants. **1988**, 205-210

- 75 Besitzt R-(1)-Deprenyl möglicherweise eine Schutzwirkung beim Morbus Parkinson?. **1988**, 73-84
- 74 Selegilin in der Früh- und Spätphase des Morbus Parkinson. **1988**, 109-117
- 73 Monoamine Oxidase-A and -B and the Bioactivation of MPTP-like Neurotoxins. **1988**, 343-349
- 72 Mechanism of oxidation of 1-methyl-4-phenyl-3,3-dihydropyridinium (MPDP+). **1988**, 49, 781-5
- 71 A Biological Evaluation Of Some 2?-Substituted Analogs Of MPTP. **1988**, 113-118
- 70 MPTP Neurotoxicity And The Biochemical Blood-Brain Barrier. **1988**, 93-100
- 69 Genetic and Toxin-induced Depletion of Striatal Dopamine. **1988**, 204-210
- 68 Retroviral-Mediated Gene Transfer. **1989**, 155-182
- 67 The Blood-Brain Barrier and Movement Disorders. **1989**, 341-371
- 66 Use of MPTP-Hemiparkinsonian (HP) Monkeys to Evaluate Efficacy of Tissue Implants as a Treatment for Parkinson Disease. **1990**, 769-775
- 65 Effect of MPTP on Dopamine D2 Receptors in the Aging Mouse Striatum. **1990**, 589-592
- 64 Lisuride and Proterguride Reverse MPTP-Induced Parkinsonism in the Common Marmoset. **1990**, 565-568
- 63 Cyclosporin a Enhances Neurotoxicity of N-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Mice. **1990**, 289-292
- 62 The Effect of Tetrahydroisoquinoline on the Mitochondrial Respiration. **1990**, 309-312
- 61 Astroglial ablation by the glutamate analogue gliotoxin  $\epsilon$ -amino adipic acid prevents l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal neuronal death. **1990**, 519-528
- 60 Biochemical Studies on Predisposition to Parkinson Disease. **1990**, 231-240
- 59 Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP. **1990**, 32, 217-27
- 58 Monoamine oxidase-mediated activation of MPTP and related compounds. **1991**, 357-369

57 Mitochondrial energy crisis as a mechanism for nigral cell death. **1991**, 61-72

56 Hereditary Variation of Liver Enzymes involved with Detoxification and Neurodegenerative Disease. **1991**, 431-435

55 Evidence in laboratory animal studies of genetic predisposition to effects of toxic chemicals. **1991**, 81-89

54 Tyrosine hydroxylase in relation to Parkinson's disease: a historical overview and future prospect. **1991**, 1-11

53 The Importance of MPP+ Localization for the Manifestation of MPTP-Induced Neurotoxicity. **1991**, 501-510

52 Neurotransmitters. **1992**, 167-205

51 Medicinal Chemistry of Present and Future MAO-B Inhibitors. **1993**, 75-108

1

50 ILLICIT DRUGS OF ABUSE. **1993**, 20, 221-230

3

49 Target-Specific Outgrowth from Grafted Dopaminergic Neurons. **1994**, 567-579

48 Vitamin E and Other Antioxidants in Neurological Function and Disease. **1994**, 535-565

2

47 The MPTP Model of Parkinson's Disease in the Mouse. Modafinil: New Potential Neuroprotective Agent. **1994**, 409-423

46 Novel toxins and Parkinson's disease: N-methylation and oxidation as metabolic bioactivation of neurotoxin. **1994**, 41, 197-205

12

45 Perinatal Intake of Polychlorinated Biphenyl (PCB). **1994**, 281-299

44 References. **1995**, 707-850

43 Up to what extent has the etiology of Parkinson's disease been elucidated?. **1995**, 41, 195-206

42 Neurotoxins and Neurodegenerative Diseases. **1995**, 671-686

41 Movement Disorders. **1995**, 143-174

40 Drug Interactions and Drug-Metabolising Enzymes. **1996**, 151-171

39	Long-Term Safety and Efficacy of Selegiline in the Treatment of Parkinson's Disease. <b>1997</b> , 331-337		
38	Etiological Considerations. <b>1997</b> , 153-185		
37	pro-α-Methylimidazoleacetic Acid: A Potential Neurotoxin in Brain?. <b>1998</b> , 171-187		
36	An Animal Model of Parkinson's Disease Prepared by Endogenous N -Methyl(R)Salsolinol. <b>1998</b> , 41-61		3
35	ROCK1/Drp1-mediated aberrant mitochondrial fission is crucial for dopaminergic nerve cell apoptosis.		
34	Mitochondrial Dysfunction in Aging and Neurodegeneration. <b>2019</b> , 76-101		
33	Basal Ganglia. <b>2020</b> , 591-667		0
32	Functional neural electron transport. <b>2020</b> , 25-111		0
31	Modeling and Simulation of Deep Brain Stimulation in Parkinson's Disease. 62-120		1
30	Pharmacology and Toxicology of MPTP: A Neurotoxic By-Product of Illicit Designer Drug Chemistry. <b>1989</b> , 197-210		
29	Inactivation of monoamine oxidase by 3,3-dimethyl analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenyl-2,3-dihydropyridinium ion. <b>1989</b> , 264, 21516-21521		4
28	Parkinson's disease in 1984: an update. <b>1984</b> , 131, 1031-7		6
27	Severe acute neurotoxicity reflects absolute intra-carotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine dose in non-human primates. <b>2021</b> , 366, 109406		0
26	T cells, α-Synuclein and Parkinson disease.. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2022</b> , 184, 439-455	3	0
25	Sleep and circadian rhythms in Parkinson's disease and preclinical models.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 2	19	0
24	Zebrafish, Medaka and Turquoise Killifish for Understanding Human Neurodegenerative/Neurodevelopmental Disorders.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	5
23	Environmental factors in Parkinson's disease: new insights into the molecular mechanisms. <i>Toxicology Letters</i> , <b>2021</b> , 356, 1-1	4.4	0
22	Mitophagy and Neurodegeneration: Between the Knowns and the Unknowns.. <i>Frontiers in Cell and Developmental Biology</i> , <b>2022</b> , 10, 837337	5.7	1

21	A hypothetical proposal to employ meperidine and tamoxifen in treatment of glioblastoma. Role of P-glycoprotein, ceramide and metabolic pathways.. <i>Clinical Neurology and Neurosurgery</i> , <b>2022</b> , 215, 107208	2.8	0
20	Mitochondria in neurodegeneration. <i>Current Opinion in Physiology</i> , <b>2022</b> , 100532	2.6	0
19	Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	2
18	CHAPTER 11. At the Intersection Between Mitochondrial Dysfunction and Lysosomal Autophagy: Role of PD-Related Neurotoxins and Gene Products. <i>Issues in Toxicology</i> , 325-388	0.3	
17	Parkinson's disease: pathological mechanisms and actions of piribedil. <i>Journal of Neurology</i> , <b>1992</b> , 239 Suppl 1, S2-8	5.5	12
16	Deterioration of dopaminergic pathways and alterations in cognition and motor functions. <i>Journal of Neurology</i> , <b>1992</b> , 239 Suppl 1, S9-12	5.5	
15	Mitochondrial Dysfunction in Aging and Neurodegeneration. <b>2022</b> , 253-278		
14	Transplantation of fetal brain tissue. <b>1988</b> , 23, 143-157		0
13	Mitochondrial electron transport chain defects modify Parkinson's disease phenotypes in a Drosophila model. <i>Neurobiology of Disease</i> , <b>2022</b> , 105803	7.5	1
12	An insight into reactivity and bioactivity properties of quorum sensing peptides against PDE10A: a computational peptidology approach. <i>Journal of Molecular Modeling</i> , <b>2022</b> , 28,	2	0
11	The relationship of alpha-synuclein to mitochondrial dynamics and quality control. 15,		0
10	Parkinson's disease rodent models: Are they suitable for DBS research?. <b>2022</b> , 380, 109687		0
9	Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. <b>2022</b> , 19,		3
8	Mitochondrial protein import stress potentiates neurodegeneration in a mouse model of Parkinson's disease.		0
7	Quantitative Determination of Endogenous Tetrahydroisoquinolines, Potential Parkinson's Disease Biomarkers, in Mammals.		0
6	Microwave-assisted functionalization of graphene oxide with amino acid behaviour on the chemical constituents and specific molecular pathways of pearl millet grains under saline conditions. <b>2022</b> , 2, 100020		0
5	Mitochondria: how eminent in ageing and neurodegenerative disorders?.		1
4	MPTP Neurotoxicity: Actions, Mechanisms, and Animal Modeling of Parkinson's Disease. <b>2022</b> , 443-483		0

- 3 Glutamate as a Neurotoxin. **2022**, 769-801
- 2 Parkinson Disease, Parkinsonisms, and Mitochondria: the Role of Nuclear and Mitochondrial DNA. **2023**, 23, 131-147
- 1 Neurodegeneration, Mitochondria, and Antibiotics. **2023**, 13, 416